Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31661952,Kd,"As expected, Fc-fusion does not affect the in vitro enzyme activity and thermal stability of the enzyme and that Fc-E196-301 can favorably bind FcRn with Kd = 386 ± 35 nM.",PEGylation but Not Fc-Fusion Improves in Vivo Residence Time of a Thermostable Mutant of Bacterial Cocaine Esterase. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31661952/),nM,386,1246,DB00907,Cocaine
,31661952,t1/2,"However, Fc-fusion does not prolong the in vivo half-life of E196-301 at all; Fc-E196-301 and E196-301 have essentially the same PK profile (t1/2 = 0.4 ± 0.1 h) in rats.",PEGylation but Not Fc-Fusion Improves in Vivo Residence Time of a Thermostable Mutant of Bacterial Cocaine Esterase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31661952/),h,0.4,1247,DB00907,Cocaine
,31661952,elimination t1/2,"It has also been demonstrated that both E196-301 and PEG-E196-301 have dose-dependent in vivo half-lives (e.g., 19.9 ± 6.4 h for the elimination t1/2 of 30 mg/kg PEG-E196-301), as the endogenous proteolytic enzymes responsible for proteolysis of E196-301 (PEGylated or not) are nearly saturated by the high plasma concentration produced by a high dose of E196-301 or PEG-E196-301.",PEGylation but Not Fc-Fusion Improves in Vivo Residence Time of a Thermostable Mutant of Bacterial Cocaine Esterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31661952/),h,19.9,1248,DB00907,Cocaine
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.0,3336,DB00907,Cocaine
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.3,3337,DB00907,Cocaine
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,11,3338,DB00907,Cocaine
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,12,3339,DB00907,Cocaine
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],100,3340,DB00907,Cocaine
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],58.4,3341,DB00907,Cocaine
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],39.5,3342,DB00907,Cocaine
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],21.8,3343,DB00907,Cocaine
,12485948,clearance,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [min],0.91,6083,DB00907,Cocaine
,12485948,clearance,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [min],0.79,6084,DB00907,Cocaine
,12485948,volumes of distribution,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [kg],2.6,6085,DB00907,Cocaine
,12485948,volumes of distribution,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [kg],2.7,6086,DB00907,Cocaine
,24733787,Kd,The recombinant h2E2 protein was produced in vitro from a transfected mammalian cell line and retained high affinity (4 nM Kd) and specificity for cocaine over its inactive metabolites benzoylecgonine (BE) and ecgonine methyl ester.,A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733787/),nM,4,8836,DB00907,Cocaine
,24733787,terminal elimination half-life,"In rats, pharmacokinetic studies of h2E2 (120 mg/kg i.v.) showed a long terminal elimination half-life of 9.0 days and a low volume of distribution at steady state (Vdss) of 0.3 l/kg.",A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733787/),d,9.0,8837,DB00907,Cocaine
,24733787,volume of distribution at steady state (Vdss),"In rats, pharmacokinetic studies of h2E2 (120 mg/kg i.v.) showed a long terminal elimination half-life of 9.0 days and a low volume of distribution at steady state (Vdss) of 0.3 l/kg.",A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733787/),[l] / [kg],0.3,8838,DB00907,Cocaine
,1914786,half-life,The mean half-life of cocaine in the fetus across doses (4.4-5.0 min) was similar to that in the ewe (4.0-5.6 min).,Disposition of cocaine in pregnant sheep. I. Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914786/),min,4.4-5.0,10215,DB00907,Cocaine
,1914786,half-life,The mean half-life of cocaine in the fetus across doses (4.4-5.0 min) was similar to that in the ewe (4.0-5.6 min).,Disposition of cocaine in pregnant sheep. I. Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914786/),min,4.0-5.6,10216,DB00907,Cocaine
,30042675,half-lives,"PK analyses demonstrated good absorption with peak plasma maximum concentrations (Cmax) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses.","A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30042675/),h,17,15057,DB00907,Cocaine
,7938127,latency to,"The duration of all marihuana- and cocaine-related positive subjective effects was unchanged when both drugs were given, but marihuana pretreatment significantly reduced the latency to cocaine effects, from 1.87 to 0.53 min, and decreased the duration of dysphoric or bad effects, from 2.1 to 0.5 min.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),min,1.87,16304,DB00907,Cocaine
,7938127,latency to,"The duration of all marihuana- and cocaine-related positive subjective effects was unchanged when both drugs were given, but marihuana pretreatment significantly reduced the latency to cocaine effects, from 1.87 to 0.53 min, and decreased the duration of dysphoric or bad effects, from 2.1 to 0.5 min.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),min,0.53,16305,DB00907,Cocaine
,7938127,Peak plasma cocaine levels,"Peak plasma cocaine levels were 122.8 +/- 26.6 ng/ml after placebo marihuana, but pretreatment with the high-dose marihuana resulted in a significant increase in peak cocaine levels (233.8 +/- 19.2 ng/ml) and the apparent bioavailability as determined by area under the curve (AUC) analysis.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),[ng] / [ml],122.8,16306,DB00907,Cocaine
,7938127,peak cocaine levels,"Peak plasma cocaine levels were 122.8 +/- 26.6 ng/ml after placebo marihuana, but pretreatment with the high-dose marihuana resulted in a significant increase in peak cocaine levels (233.8 +/- 19.2 ng/ml) and the apparent bioavailability as determined by area under the curve (AUC) analysis.",Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938127/),[ng] / [ml],233.8,16307,DB00907,Cocaine
,8059340,Peak heart binding,Peak heart binding of [11C]cocaine was high (0.038-0.055%/g) and clearance was rapid (t1/2 from peak: 2.5-9 min) for both tracer doses and a pharmacological dose.,PET studies of cocaine inhibition of myocardial norepinephrine uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059340/),[%] / [g],0.038-0.055,16336,DB00907,Cocaine
,8059340,t1/2 from peak,Peak heart binding of [11C]cocaine was high (0.038-0.055%/g) and clearance was rapid (t1/2 from peak: 2.5-9 min) for both tracer doses and a pharmacological dose.,PET studies of cocaine inhibition of myocardial norepinephrine uptake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059340/),min,2.5-9,16337,DB00907,Cocaine
,1294836,half-life,"For patients receiving two successive doses of COC intravenously (IV) or by smoking (SM), the average half-life of COC was found to be between 38 and 39 minutes, regardless of the dose or route of administration.",Concentration of cocaine and metabolites in plasma of humans following intravenous administration and smoking of cocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294836/),min,38 and 39,16651,DB00907,Cocaine
,1294836,maximum COC concentration,The maximum COC concentration observed was 1.2 mg/L following a total administration of 316 mg of COC over 90 min.,Concentration of cocaine and metabolites in plasma of humans following intravenous administration and smoking of cocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294836/),[mg] / [l],1.2,16652,DB00907,Cocaine
,10813548,urine concentration ratios,Ecgonine methylester/benzoylecgonine urine concentration ratios did not alter with duration of infusion (1.2+/-0.2 and 1.1+/-0.2 in the high-dose group at the first and last time point) and were not affected by the dose of cocaine (1.3+/-0.6 and 1.2+/-0.1 at corresponding times in the low-dose group (P > 0.05)).,"Chronic continuous cocaine infusion in rats: effect on urine cocaine, ecgonine methylester and benzoylecgonine concentrations and bolus-dose cocaine pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813548/),,1.2,19234,DB00907,Cocaine
,10813548,urine concentration ratios,Ecgonine methylester/benzoylecgonine urine concentration ratios did not alter with duration of infusion (1.2+/-0.2 and 1.1+/-0.2 in the high-dose group at the first and last time point) and were not affected by the dose of cocaine (1.3+/-0.6 and 1.2+/-0.1 at corresponding times in the low-dose group (P > 0.05)).,"Chronic continuous cocaine infusion in rats: effect on urine cocaine, ecgonine methylester and benzoylecgonine concentrations and bolus-dose cocaine pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813548/),,1.1,19235,DB00907,Cocaine
,10813548,urine concentration ratios,Ecgonine methylester/benzoylecgonine urine concentration ratios did not alter with duration of infusion (1.2+/-0.2 and 1.1+/-0.2 in the high-dose group at the first and last time point) and were not affected by the dose of cocaine (1.3+/-0.6 and 1.2+/-0.1 at corresponding times in the low-dose group (P > 0.05)).,"Chronic continuous cocaine infusion in rats: effect on urine cocaine, ecgonine methylester and benzoylecgonine concentrations and bolus-dose cocaine pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813548/),,1.3,19236,DB00907,Cocaine
,10813548,urine concentration ratios,Ecgonine methylester/benzoylecgonine urine concentration ratios did not alter with duration of infusion (1.2+/-0.2 and 1.1+/-0.2 in the high-dose group at the first and last time point) and were not affected by the dose of cocaine (1.3+/-0.6 and 1.2+/-0.1 at corresponding times in the low-dose group (P > 0.05)).,"Chronic continuous cocaine infusion in rats: effect on urine cocaine, ecgonine methylester and benzoylecgonine concentrations and bolus-dose cocaine pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10813548/),,1.2,19237,DB00907,Cocaine
,17879975,Vd,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),[l] / [kg],8.69-34.3,20311,DB00907,Cocaine
,17879975,Vd,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),[l] / [kg],0.9,20312,DB00907,Cocaine
,17879975,elimination (t l/2,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),h,4.1-5.4,20313,DB00907,Cocaine
,17879975,elimination (t l/2,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),h,0.5,20314,DB00907,Cocaine
,17879975,Brain-to-plasma partition coefficients,Brain-to-plasma partition coefficients were 1.3-2.5 vs.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),,1.3-2.5,20315,DB00907,Cocaine
greater,12954808,time to peak DAT occupancy,The time to peak DAT occupancy for the cocaine analogs was greater than 30 min.,The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954808/),min,30,21077,DB00907,Cocaine
,1491036,detection limit,"With an ultraviolet detector operated at 230 nm, a linear response was observed from 0.05 to 2.0 micrograms/ml with a detection limit of 5 ng/ml for cocaethylene, cocaine and norcocaine.","Determination of cocaethylene, cocaine and their metabolites in rat serum microsamples by high-performance liquid chromatography, and its application to pharmacokinetic studies in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491036/),[ng] / [ml],5,29066,DB00907,Cocaine
,1435091,rate constant,"The mean rate constant and mean half-life for cocaine disappearance from hair were 0.212 +/- 0.005 day-1 and 3.31 +/- 0.09 days, respectively, and the mean rate constant and mean half-life for benzoylecgonine disappearance from hair were 0.098 +/- 0.006 day-1 and 6.90 +/- 0.28 days, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),1/[d],0.212,29537,DB00907,Cocaine
,1435091,half-life,"The mean rate constant and mean half-life for cocaine disappearance from hair were 0.212 +/- 0.005 day-1 and 3.31 +/- 0.09 days, respectively, and the mean rate constant and mean half-life for benzoylecgonine disappearance from hair were 0.098 +/- 0.006 day-1 and 6.90 +/- 0.28 days, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),d,3.31,29538,DB00907,Cocaine
,1435091,rate constant,"The mean rate constant and mean half-life for cocaine disappearance from hair were 0.212 +/- 0.005 day-1 and 3.31 +/- 0.09 days, respectively, and the mean rate constant and mean half-life for benzoylecgonine disappearance from hair were 0.098 +/- 0.006 day-1 and 6.90 +/- 0.28 days, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),1/[d],0.098,29539,DB00907,Cocaine
,1435091,half-life,"The mean rate constant and mean half-life for cocaine disappearance from hair were 0.212 +/- 0.005 day-1 and 3.31 +/- 0.09 days, respectively, and the mean rate constant and mean half-life for benzoylecgonine disappearance from hair were 0.098 +/- 0.006 day-1 and 6.90 +/- 0.28 days, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),d,6.90,29540,DB00907,Cocaine
,1435091,plasma concentrations,"The mean plasma concentrations of cocaine on Day 25 for the 5, 10, and 20 mg/kg doses of cocaine were 508 +/- 42, 852 +/- 95, and 2027 +/- 75 ng/mL, respectively, and the mean plasma benzoylecgonine levels for the 5, 10, and 20 mg/kg doses of cocaine were 49.9 +/- 7.0, 103.3 +/- 9.3, and 191.0 +/- 16.0 ng/mL, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),[ng] / [ml],508,29541,DB00907,Cocaine
,1435091,plasma concentrations,"The mean plasma concentrations of cocaine on Day 25 for the 5, 10, and 20 mg/kg doses of cocaine were 508 +/- 42, 852 +/- 95, and 2027 +/- 75 ng/mL, respectively, and the mean plasma benzoylecgonine levels for the 5, 10, and 20 mg/kg doses of cocaine were 49.9 +/- 7.0, 103.3 +/- 9.3, and 191.0 +/- 16.0 ng/mL, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),[ng] / [ml],852,29542,DB00907,Cocaine
,1435091,plasma concentrations,"The mean plasma concentrations of cocaine on Day 25 for the 5, 10, and 20 mg/kg doses of cocaine were 508 +/- 42, 852 +/- 95, and 2027 +/- 75 ng/mL, respectively, and the mean plasma benzoylecgonine levels for the 5, 10, and 20 mg/kg doses of cocaine were 49.9 +/- 7.0, 103.3 +/- 9.3, and 191.0 +/- 16.0 ng/mL, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),[ng] / [ml],2027,29543,DB00907,Cocaine
,1435091,plasma concentrations,"The mean plasma concentrations of cocaine on Day 25 for the 5, 10, and 20 mg/kg doses of cocaine were 508 +/- 42, 852 +/- 95, and 2027 +/- 75 ng/mL, respectively, and the mean plasma benzoylecgonine levels for the 5, 10, and 20 mg/kg doses of cocaine were 49.9 +/- 7.0, 103.3 +/- 9.3, and 191.0 +/- 16.0 ng/mL, respectively.",The accumulation and disappearance of cocaine and benzoylecgonine in rat hair following prolonged administration of cocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435091/),ng,49.,29544,DB00907,Cocaine
,20086035,half-life,"In vitro kinetic analyses reveal that CocE-L169K/G173Q displays a half-life of 2.9 days at 37 degrees C, which represents a 340-fold improvement over wt and is 15-fold greater than previously reported mutants.",A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086035/),d,2.9,31756,DB00907,Cocaine
,20086035,half-life,"Termination of the in vivo effects of CoCE seems to be dependent on, but not proportional to, its clearance from plasma as its half-life is approximately 2.3 h and similar to that of wt CocE (2.2 h).",A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086035/),h,2.3,31757,DB00907,Cocaine
,20086035,half-life,"Termination of the in vivo effects of CoCE seems to be dependent on, but not proportional to, its clearance from plasma as its half-life is approximately 2.3 h and similar to that of wt CocE (2.2 h).",A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086035/),h,2.2,31758,DB00907,Cocaine
,10430537,AU,"The ratios of the area under the cocaine concentration-time curve (AUC) between the olfactory bulb and plasma at early times following in administration were significantly higher than those obtained after the iv dose (13.4 +/- 5.56 vs 6.16 +/- 0.94, p < 0.05, for AUC ratio up to 2 min post dose; 9.39 +/- 1.47 vs 7.34 +/- 0.59, p < 0.05, for AUC ratio up to 4 min post dose).",Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430537/),,9,35344,DB00907,Cocaine
,7924763,CBF,"COC decreased CBF and CMRO2 from 75 to 64 and 4.27 to 3.91 ml/min/100 g, respectively, at 4 min with reduced flow to all brain regions (p < 0.05) which returned to baseline by 10 min.",Pharmacokinetics and effect of cocaine on cerebral blood flow in the newborn. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924763/),[ml] / [100·g·min],75 to 64,37341,DB00907,Cocaine
,7924763,CMRO2,"COC decreased CBF and CMRO2 from 75 to 64 and 4.27 to 3.91 ml/min/100 g, respectively, at 4 min with reduced flow to all brain regions (p < 0.05) which returned to baseline by 10 min.",Pharmacokinetics and effect of cocaine on cerebral blood flow in the newborn. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924763/),[ml] / [100·g·min],4.27 to 3.91,37342,DB00907,Cocaine
,7924763,t1/2,"COC was rapidly metabolized with a t1/2 of 43 min and peak plasma concentration of 1,172 ng/ml.",Pharmacokinetics and effect of cocaine on cerebral blood flow in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924763/),min,43,37343,DB00907,Cocaine
,7924763,peak plasma concentration,"COC was rapidly metabolized with a t1/2 of 43 min and peak plasma concentration of 1,172 ng/ml.",Pharmacokinetics and effect of cocaine on cerebral blood flow in the newborn. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924763/),[ng] / [ml],"1,172",37344,DB00907,Cocaine
,734226,elimination half-life,The plasma concentration-time data yield an elimination half-life of approximately 1 hour and the data suggest that only about 20% of an oral dose of cocaine is absorbed intact into the systemic circulation.,Kinetics of pharmacologic response to cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/734226/),h,1,39141,DB00907,Cocaine
,734226,rate of decline of response,"The rate of decline of response was found to be 0.0221 ""high""/min.",Kinetics of pharmacologic response to cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/734226/),high,0.0221,39142,DB00907,Cocaine
,11888059,Plasma,"Plasma and brain recoveries of AHN-1055 were 95 and 79%, respectively.","Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888059/),%,95,41532,DB00907,Cocaine
,11888059,brain recoveries,"Plasma and brain recoveries of AHN-1055 were 95 and 79%, respectively.","Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888059/),%,79,41533,DB00907,Cocaine
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,31.5,42114,DB00907,Cocaine
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,29.1,42115,DB00907,Cocaine
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,21.4,42116,DB00907,Cocaine
,29375408,brain: serum ratios,"Mean brain: serum ratios were 1:1.19 (MEPH) and 1:1.91 (nor-MEPH), maximum concentrations were observed at 30 min; at 2 and 4 h after administration, nor-MEPH concentrations were higher compared to the parent drug.","Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29375408/),,1,43570,DB00907,Cocaine
,29375408,brain: serum ratios,"Mean brain: serum ratios were 1:1.19 (MEPH) and 1:1.91 (nor-MEPH), maximum concentrations were observed at 30 min; at 2 and 4 h after administration, nor-MEPH concentrations were higher compared to the parent drug.","Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29375408/),,1:,43571,DB00907,Cocaine
,25475011,Cmax,"MDPV exhibited the highest Cmax at all doses (74.2-271.3 μg/l) and 4-OH-3-MeOH-PV the highest AUC (11 366-47 724 minutes per μg/l), being the predominant metabolite.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),[μg] / [l],74.2-271.3,45214,DB00907,Cocaine
,25475011,AUC,"MDPV exhibited the highest Cmax at all doses (74.2-271.3 μg/l) and 4-OH-3-MeOH-PV the highest AUC (11 366-47 724 minutes per μg/l), being the predominant metabolite.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),[min] / [l·μg],11 366-47 724,45215,DB00907,Cocaine
,25475011,time to Cmax (Tmax ),"MDPV time to Cmax (Tmax ) was 12.9-18.6 minutes, while 3,4-catechol-PV and 4-OH-3-MeO-PV peaked later with Tmax 188.6-240 minutes after s.c. dosing.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),min,12.9-18.6,45216,DB00907,Cocaine
,25475011,Tmax,"MDPV time to Cmax (Tmax ) was 12.9-18.6 minutes, while 3,4-catechol-PV and 4-OH-3-MeO-PV peaked later with Tmax 188.6-240 minutes after s.c. dosing.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),min,188.6-240,45217,DB00907,Cocaine
,28008717,flow rate,"The biological samples were extracted by liquid-liquid extraction and separated on a Bonshell ASB C18 column (2.1 × 100 mm, 2.7 μm, Agela) with gradient mobile phase at the flow rate of 0.2 mL/min.","Pharmacokinetics, tissue distribution, and excretion studies of l-isocorypalmine using ultra high performance liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008717/),[ml] / [min],0.2,51746,DB00907,Cocaine
,7242115,absorption half-life t1/2(ab),From analysis of previously published data the absorption half-life t1/2(ab) is approximately 8 min for gastrointestinal and for nasal inhalation absorption.,Cocaine pharmacokinetics in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7242115/),min,8,52115,DB00907,Cocaine
,7242115,bioavailability,The bioavailability for nasal inhalation is approximately 60%.,Cocaine pharmacokinetics in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7242115/),%,60,52116,DB00907,Cocaine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],3534,54386,DB00907,Cocaine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],"20,580",54387,DB00907,Cocaine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),,6,54388,DB00907,Cocaine
,8926729,Peak heroin concentrations,"Peak heroin concentrations in saliva after smoking heroin base ranged from 3534 (2.6 mg) to 20,580 ng/mL (5.2 mg), and after intravenous administration, concentrations ranged from 6 (10 mg heroin HCl to 30 ng/mL (12 mg heroin HCl.",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],30,54389,DB00907,Cocaine
,8926729,detection times,Heroin concentrations in saliva after smoking declined slowly; detection times ranged from 4 to 24 h.,Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),h,4 to 24,54390,DB00907,Cocaine
,8926729,Peak saliva cocaine concentrations,"Peak saliva cocaine concentrations after intravenous administration ranged from 428 to 1927 ng/mL (N = 7); after smoking, they ranged from 15,852 to 504,880 ng/mL (N = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],428 to 1927,54391,DB00907,Cocaine
,8926729,Peak saliva cocaine concentrations,"Peak saliva cocaine concentrations after intravenous administration ranged from 428 to 1927 ng/mL (N = 7); after smoking, they ranged from 15,852 to 504,880 ng/mL (N = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],"15,852 to 504,880",54392,DB00907,Cocaine
,8926729,Peak plasma cocaine concentrations,"Peak plasma cocaine concentrations after intravenous administration ranged from 122 to 442 ng/mL A = 7), and after smoking, concentrations ranged from 46 to 291 ng/mL A = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],122 to 442,54393,DB00907,Cocaine
,8926729,Peak plasma cocaine concentrations,"Peak plasma cocaine concentrations after intravenous administration ranged from 122 to 442 ng/mL A = 7), and after smoking, concentrations ranged from 46 to 291 ng/mL A = 7).",Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],46 to 291,54394,DB00907,Cocaine
,8926729,Peak saliva AEME concentrations,Peak saliva AEME concentrations were achieved at 2 min and ranged from 558 to 4374 ng/mL (N = 7).,Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926729/),[ng] / [ml],558 to 4374,54395,DB00907,Cocaine
,11521899,maximum plasma concentrations,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[μg] / [ml],5.74,55049,DB00907,Cocaine
,11521899,clearances,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[μg] / [ml],7.26,55050,DB00907,Cocaine
,11521899,clearances,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[ml] / [kg·min],135.7,55051,DB00907,Cocaine
,11521899,clearances,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[ml] / [kg·min],98.5,55052,DB00907,Cocaine
,11521899,areas under the curve,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[ml] / [kg·min],98.5,55053,DB00907,Cocaine
,11521899,areas under the curve,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[min·μg] / [ml],44.23,55054,DB00907,Cocaine
,11521899,areas under the curve,"The maximum plasma concentrations, clearances of the drug, and areas under the curve for male and female rats were 5.74 and 7.26 microg/ml, 135.7 and 98.5 ml/kg x min, and 44.23 and 60.92 microg x min/ml, respectively.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[min·μg] / [ml],60.92,55055,DB00907,Cocaine
,11521899,terminal t(1/2),"The drug was cleared very rapidly from the systemic circulation, with a terminal t(1/2) of 7 to 10 min and a mean residence time of about 11 min for both sexes.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),min,7 to 10,55056,DB00907,Cocaine
,11521899,mean residence time,"The drug was cleared very rapidly from the systemic circulation, with a terminal t(1/2) of 7 to 10 min and a mean residence time of about 11 min for both sexes.",Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),min,11,55057,DB00907,Cocaine
,11521899,volume of distribution,The volume of distribution was approximately 1 l/kg.,Analysis of 2beta-carbomethoxy-3beta-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma. Pharmacokinetic profile in male and female Sprague-Dawley rats evaluated by capillary electrophoresis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521899/),[l] / [kg],1,55058,DB00907,Cocaine
,9512065,t1/2,"Specifically, we observed that at 5 min onward, B6 mice cleared cocaine from the brain with a t1/2 estimated at 22.3 min, while distribution in D2 mice appeared to be incomplete until 15 min with a subsequent t1/2 estimated at 11.2 min.",Distribution and clearance of cocaine in brain is influenced by genetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512065/),min,22.3,55432,DB00907,Cocaine
,9512065,t1/2,"Specifically, we observed that at 5 min onward, B6 mice cleared cocaine from the brain with a t1/2 estimated at 22.3 min, while distribution in D2 mice appeared to be incomplete until 15 min with a subsequent t1/2 estimated at 11.2 min.",Distribution and clearance of cocaine in brain is influenced by genetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512065/),min,11.2,55433,DB00907,Cocaine
,19821842,peak half-clearance,"Moreover, the clearance of [(11)C]cocaine from the brain was faster for ISO (peak half-clearance 15.8 +/- 2.8 min) than for alpha-CHLOR (27.5 +/- 0.6 min), and the ratio of specific to non-specific binding of [(11)C]cocaine in the brain was higher for ISO- (3.37 +/- 0.32) than for alpha-CHLOR-anesthetized rats (2.24 +/- 0.4).",Differential effects of anesthetics on cocaine's pharmacokinetic and pharmacodynamic effects in brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19821842/),min,15.8,56096,DB00907,Cocaine
,19821842,peak half-clearance,"Moreover, the clearance of [(11)C]cocaine from the brain was faster for ISO (peak half-clearance 15.8 +/- 2.8 min) than for alpha-CHLOR (27.5 +/- 0.6 min), and the ratio of specific to non-specific binding of [(11)C]cocaine in the brain was higher for ISO- (3.37 +/- 0.32) than for alpha-CHLOR-anesthetized rats (2.24 +/- 0.4).",Differential effects of anesthetics on cocaine's pharmacokinetic and pharmacodynamic effects in brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19821842/),min,27.5,56097,DB00907,Cocaine
,2688863,Elimination half-lives,Elimination half-lives of cocaine in man estimated from serial plasma concentration are relatively short and range from 0.5 to 1.1 h after i.v. and 0.9-1.5 h after administration by the nasal or oral route.,Cocaine: pharmacokinetics and biotransformation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2688863/),h,0.5 to 1.1,57613,DB00907,Cocaine
,2688863,Elimination half-lives,Elimination half-lives of cocaine in man estimated from serial plasma concentration are relatively short and range from 0.5 to 1.1 h after i.v. and 0.9-1.5 h after administration by the nasal or oral route.,Cocaine: pharmacokinetics and biotransformation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2688863/),h,0.9-1.5,57614,DB00907,Cocaine
,2688863,bioavailability,The bioavailability after nasal inhalation is about 60%.,Cocaine: pharmacokinetics and biotransformation in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2688863/),%,60,57615,DB00907,Cocaine
,22264200,half-life,Pharmacokinetic studies showed that Albu-CocH (5 mg/kg) had a half-life of 56.6 hours in squirrel monkeys.,Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264200/),h,56.6,61494,DB00907,Cocaine
,11920936,maximum concentration,"Benzoylecgonine reached a mean (+/- SEM) maximum concentration of 531.9 +/- 168.7 ng ml(-1) after 4 h, whereas ecgonine methyl ester peaked 2 h after injection at a concentration of 97.2 +/- 26.5 ng ml(-1).",Determination of the highest no-effect dose (HNED) and of the elimination pattern for cocaine in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920936/),[ng] / [ml],531.9,62048,DB00907,Cocaine
,2565204,V beta,The volume of distribution of cocaine is low (2.70 liter/kg for V beta).,"Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),[l] / [kg],2.70,64834,DB00907,Cocaine
,2565204,half-time,Absorption of smoked cocaine was rapid (half-time of 1.1 min).,"Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),min,1.1,64835,DB00907,Cocaine
,2565204,half-time,Absorption after ni was slower (half-time of 11.7 min).,"Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),min,11.7,64836,DB00907,Cocaine
,2565204,half-life,"After iv injection, a rapid distribution phase was observed (half-life of 11 min) and the elimination half-life was 78 min.","Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),min,11,64837,DB00907,Cocaine
,2565204,elimination half-life,"After iv injection, a rapid distribution phase was observed (half-life of 11 min) and the elimination half-life was 78 min.","Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),min,78,64838,DB00907,Cocaine
,2565204,half-life,"In 16 subjects divided into three groups based on routes, the half-life based on the average rate constant was 69 min.","Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),min,69,64839,DB00907,Cocaine
,2565204,Bioavailability,Bioavailability was good after ni (80%).,"Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565204/),%,80,64840,DB00907,Cocaine
,7357795,elimination half-life (t 1/2),The mean elimination half-life (t 1/2) for cocaine by the intranasal route to 7 subjects was 75 +/- 5 min (mean +/- SE).,Intranasal and oral cocaine kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357795/),min,75,68250,DB00907,Cocaine
,7357795,t 1/2,The mean t 1/2 after oral administration to 4 subjects was 48 +/- 3 min.,Intranasal and oral cocaine kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357795/),min,48,68251,DB00907,Cocaine
,9266810,beta-t(1/2),Most of the enzyme could be recovered in the plasma immediately after administration and remained active with a beta-t(1/2) of 21.6 +/- 2.4 hr.,Cocaine detoxification by human plasma butyrylcholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266810/),h,21.6,75393,DB00907,Cocaine
,10372652,Km,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.53,77305,DB00907,Cocaine
,10372652,Km,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.97,77306,DB00907,Cocaine
,10372652,Km,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),[pM] / [mg·min],390,77307,DB00907,Cocaine
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.97,77308,DB00907,Cocaine
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.56,77309,DB00907,Cocaine
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),[pM] / [mg·min],233,77310,DB00907,Cocaine
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),[pM] / [mg·min],60,77311,DB00907,Cocaine
,14729118,satiety threshold,"Analysis of the mean intervals as a function of unit doses generated values for the mean satiety threshold of cocaine and WIN 35,428 of 6.10 and 0.87 micromol/kg, respectively.","The self-administration of WIN 35,428 and cocaine: comparisons of satiety threshold and elimination half-life in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14729118/),[μM] / [kg],6.10,77404,DB00907,Cocaine
,14729118,satiety threshold,"Analysis of the mean intervals as a function of unit doses generated values for the mean satiety threshold of cocaine and WIN 35,428 of 6.10 and 0.87 micromol/kg, respectively.","The self-administration of WIN 35,428 and cocaine: comparisons of satiety threshold and elimination half-life in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14729118/),[μM] / [kg],0.87,77405,DB00907,Cocaine
,14729118,t(1/2),"The mean t(1/2) for cocaine and WIN 35,428 were 11.1 and 69.4 min, respectively.","The self-administration of WIN 35,428 and cocaine: comparisons of satiety threshold and elimination half-life in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14729118/),min,11.1,77406,DB00907,Cocaine
,14729118,t(1/2),"The mean t(1/2) for cocaine and WIN 35,428 were 11.1 and 69.4 min, respectively.","The self-administration of WIN 35,428 and cocaine: comparisons of satiety threshold and elimination half-life in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14729118/),min,69.4,77407,DB00907,Cocaine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],140,79102,DB00907,Cocaine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],14.7,79103,DB00907,Cocaine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],130,79104,DB00907,Cocaine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],111,79105,DB00907,Cocaine
,17625500,peak plasma METH concentrations,"METH doses were escalated over 33 weeks, with final dosages resulting in estimated peak plasma METH concentrations of 1-3 microM, a range measured in human abusers.",Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625500/),μM,1-3,88339,DB00907,Cocaine
,14561847,half-life,"Methylecgonidine clears quickly from blood with a half-life of 18 to 21 min, whereas ecgonidine has a longer half-life of 94 to 137 min.","Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561847/),min,18 to 21,88463,DB00907,Cocaine
,14561847,half-life,"Methylecgonidine clears quickly from blood with a half-life of 18 to 21 min, whereas ecgonidine has a longer half-life of 94 to 137 min.","Pharmacokinetics and pharmacodynamics of methylecgonidine, a crack cocaine pyrolyzate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561847/),min,94 to 137,88464,DB00907,Cocaine
,1552335,Half-peak clearances,"Half-peak clearances were 90 sec in the lungs, 10 min in the heart and kidneys and 22 min in the adrenals.",Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552335/),s,90,89362,DB00907,Cocaine
,1552335,Half-peak clearances,"Half-peak clearances were 90 sec in the lungs, 10 min in the heart and kidneys and 22 min in the adrenals.",Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552335/),min,10,89363,DB00907,Cocaine
,1552335,Half-peak clearances,"Half-peak clearances were 90 sec in the lungs, 10 min in the heart and kidneys and 22 min in the adrenals.",Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552335/),min,22,89364,DB00907,Cocaine
,1552335,uptake at peak,"The average uptake at peak was 0.007% (s.d., 0.001) dose/cc in the heart, 0.014% (s.d., 0.002) dose/cc in the kidney, 0.014% (s.d., 0.002) dose/cc in the liver and 0.034% (s.d., 0.001) dose/cc in the adrenals.",Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552335/),%,0.007,89365,DB00907,Cocaine
,1552335,uptake at peak,"The average uptake at peak was 0.007% (s.d., 0.001) dose/cc in the heart, 0.014% (s.d., 0.002) dose/cc in the kidney, 0.014% (s.d., 0.002) dose/cc in the liver and 0.034% (s.d., 0.001) dose/cc in the adrenals.",Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552335/),%,0.014,89366,DB00907,Cocaine
,1552335,uptake at peak,"The average uptake at peak was 0.007% (s.d., 0.001) dose/cc in the heart, 0.014% (s.d., 0.002) dose/cc in the kidney, 0.014% (s.d., 0.002) dose/cc in the liver and 0.034% (s.d., 0.001) dose/cc in the adrenals.",Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552335/),%,0.034,89367,DB00907,Cocaine
,28039926,flow rate,"Chromatographic separation was achieved on an Acquity UPLC™ BEH C18 (1.7 μm, 2.1 mm × 50 mm) column using a mobile phase [water:methanol (0.1%v/v formic acid; 50:50, %v/v)] at a flow rate of 0.2 mL/min.",Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039926/),[ml] / [min],0.2,89643,DB00907,Cocaine
,28039926,m/z transitions,Mass spectrometric detection was performed in the positive ionization mode with multiple reaction monitoring (MRM) using m/z transitions of 337 > 238 for CM304 and 319 > 220 for the IS.,Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039926/),,337,89644,DB00907,Cocaine
,28039926,m/z transitions,Mass spectrometric detection was performed in the positive ionization mode with multiple reaction monitoring (MRM) using m/z transitions of 337 > 238 for CM304 and 319 > 220 for the IS.,Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039926/),,238,89645,DB00907,Cocaine
,28039926,m/z transitions,Mass spectrometric detection was performed in the positive ionization mode with multiple reaction monitoring (MRM) using m/z transitions of 337 > 238 for CM304 and 319 > 220 for the IS.,Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039926/),,319,89646,DB00907,Cocaine
,28039926,m/z transitions,Mass spectrometric detection was performed in the positive ionization mode with multiple reaction monitoring (MRM) using m/z transitions of 337 > 238 for CM304 and 319 > 220 for the IS.,Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039926/),,220,89647,DB00907,Cocaine
,28039926,extraction recovery,"The extraction recovery ranged from 91.5 to 98.4% from spiked (7.5, 300 and 2526 ng/mL) plasma quality control samples.",Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039926/),%,91.5 to 98.4,89648,DB00907,Cocaine
,9448069,flow-rate,"The mobile phase consisted of methanol-acetonitrile-50 mM monobasic ammonium phosphate (5:7:63, v/v/v) and was maintained at a flow-rate of 0.4 ml/min.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ml] / [min],0.4,90866,DB00907,Cocaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,56.6,90867,DB00907,Cocaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,78.6,90868,DB00907,Cocaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,61.1,90869,DB00907,Cocaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,76.4,90870,DB00907,Cocaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,67.0,90871,DB00907,Cocaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],20,90872,DB00907,Cocaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],24,90873,DB00907,Cocaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],15,90874,DB00907,Cocaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],12.9,90875,DB00907,Cocaine
,10435404,F,The value of F was 4.66% which was significantly lower than the values of Fsrr (13.67%) and Frr (32.63%).,Cocaine pharmacodynamics after intravenous and oral administration in rats: relation to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435404/),%,4.66,93096,DB00907,Cocaine
,9596142,bioavailability,The pharmacokinetic results showed that the average cocaine bioavailability after i.p. administration was 71% and after oral administration was only 19.2%.,An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),%,71,94195,DB00907,Cocaine
,9596142,bioavailability,The pharmacokinetic results showed that the average cocaine bioavailability after i.p. administration was 71% and after oral administration was only 19.2%.,An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),%,19.2,94196,DB00907,Cocaine
,9596142,brain,"Cocaine was rapidly distributed into the brain, and the brain ECF/plasma distribution ratio measured as the ratio of the brain ECF AUC to the plasma AUC was 2.02 +/- 0.59.",An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),,2.02,94197,DB00907,Cocaine
,9596142,/plasma distribution ratio,"Cocaine was rapidly distributed into the brain, and the brain ECF/plasma distribution ratio measured as the ratio of the brain ECF AUC to the plasma AUC was 2.02 +/- 0.59.",An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),,2.02,94198,DB00907,Cocaine
,17023573,elimination t(1/2),"The predominantly human sequence, high-affinity anticocaine monoclonal antibody (mAb) 2E2 was cleared slowly from mouse blood by a first-order process with an elimination t(1/2) of 8.1 days.",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),d,8.1,94594,DB00907,Cocaine
,17023573,distribution t(1/2alpha),"Pharmacokinetic studies showed that the normal disappearance of cocaine from plasma was described by a two-compartment pharmacokinetic model with distribution t(1/2alpha) and terminal elimination t(1/2beta) values of 1.9 and 26.1 min, respectively.",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),min,1.9,94595,DB00907,Cocaine
,17023573,terminal elimination t(1/2beta),"Pharmacokinetic studies showed that the normal disappearance of cocaine from plasma was described by a two-compartment pharmacokinetic model with distribution t(1/2alpha) and terminal elimination t(1/2beta) values of 1.9 and 26.1 min, respectively.",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),min,26.1,94596,DB00907,Cocaine
,17023573,volume of distribution,"Consequently, 2E2 decreased the volume of distribution of cocaine from 6.0 to 0.20 l/kg, which approximated that of 2E2 (0.28 l/kg).",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),[l] / [kg],6.0,94597,DB00907,Cocaine
,17023573,volume of distribution,"Consequently, 2E2 decreased the volume of distribution of cocaine from 6.0 to 0.20 l/kg, which approximated that of 2E2 (0.28 l/kg).",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),[l] / [kg],0,94598,DB00907,Cocaine
,17023573,volume of distribution,"Consequently, 2E2 decreased the volume of distribution of cocaine from 6.0 to 0.20 l/kg, which approximated that of 2E2 (0.28 l/kg).",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),[l] / [kg],0.28,94599,DB00907,Cocaine
,17023573,elimination t(1/2),"However, cocaine was still rapidly cleared from plasma, and its elimination was now described by a single-compartment model with an elimination t(1/2) of 17 min.",A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023573/),min,17,94600,DB00907,Cocaine
,9918556,T1/2beta,Cocaine was rapidly distributed (T1/2beta = 1.09 min) and eliminated (T1/2alpha = 14.93 min).,Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),min,1.09,96364,DB00907,Cocaine
,9918556,T1/2alpha,Cocaine was rapidly distributed (T1/2beta = 1.09 min) and eliminated (T1/2alpha = 14.93 min).,Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),min,14.93,96365,DB00907,Cocaine
,9918556,free fraction,The free fraction of cocaine was 31.3-33.1% for serum cocaine concentrations of 0.5 to 1 microg/ml.,Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),%,31.3-33.1,96366,DB00907,Cocaine
,9918556,EC50,"Because the concentration at half of Emax for the shorter-response rate (EC50 = 0.467 microg/ml) was greater than that for density of reinforcement (IC50 = 0.070 microg/ml), the former began to return toward baseline sooner than the latter.",Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),[μg] / [ml],0.467,96367,DB00907,Cocaine
,9918556,IC50,"Because the concentration at half of Emax for the shorter-response rate (EC50 = 0.467 microg/ml) was greater than that for density of reinforcement (IC50 = 0.070 microg/ml), the former began to return toward baseline sooner than the latter.",Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),[μg] / [ml],0.070,96368,DB00907,Cocaine
,19088302,effect t((1/2)),"2E2 produced an initial, approximately 3-fold, increase in the cocaine priming threshold that declined toward baseline values over the subsequent 3 weeks, with an effect t((1/2)) of approximately 4 days.",The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088302/),d,4,96506,DB00907,Cocaine
,19088302,distribution,"After infusion, antibody blood concentrations declined over time, and a two-compartment pharmacokinetic model generated values for the distribution and elimination half-lives of 0.5 and 11.6 days for 2E2 and 0.4 and 6.0 days for control IgG.",The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088302/),d,0.5,96507,DB00907,Cocaine
,19088302,distribution,"After infusion, antibody blood concentrations declined over time, and a two-compartment pharmacokinetic model generated values for the distribution and elimination half-lives of 0.5 and 11.6 days for 2E2 and 0.4 and 6.0 days for control IgG.",The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088302/),d,0.4,96508,DB00907,Cocaine
,19088302,elimination half-lives,"After infusion, antibody blood concentrations declined over time, and a two-compartment pharmacokinetic model generated values for the distribution and elimination half-lives of 0.5 and 11.6 days for 2E2 and 0.4 and 6.0 days for control IgG.",The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088302/),d,11.6,96509,DB00907,Cocaine
,19088302,elimination half-lives,"After infusion, antibody blood concentrations declined over time, and a two-compartment pharmacokinetic model generated values for the distribution and elimination half-lives of 0.5 and 11.6 days for 2E2 and 0.4 and 6.0 days for control IgG.",The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088302/),d,6.0,96510,DB00907,Cocaine
,2034039,recovery,In-vitro trials showed 30.0 +/- 5.2% (mean +/- SE) recovery of cocaine in solvent.,Inhalational administration of cocaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034039/),%,30.0,98867,DB00907,Cocaine
,2034039,half-life,Cocaine administered by inhalation was eliminated with a half-life of 1.6 +/- 0.5 min (mean +/- SE) compared to 3.4 +/- 0.9 following intravenous administration (p less than 0.03).,Inhalational administration of cocaine in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034039/),min,1.6,98868,DB00907,Cocaine
,2034039,half-life,Cocaine administered by inhalation was eliminated with a half-life of 1.6 +/- 0.5 min (mean +/- SE) compared to 3.4 +/- 0.9 following intravenous administration (p less than 0.03).,Inhalational administration of cocaine in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034039/),min,3.4,98869,DB00907,Cocaine
,2034039,clearance,"Likewise, clearance values were greater following inhalation, 5532 +/- 1756 ml/min/kg, than following intravenous administration, 163 +/- 20.6 ml/min/kg (p less than 0.04).",Inhalational administration of cocaine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034039/),[ml] / [kg·min],5532,98870,DB00907,Cocaine
,2034039,clearance,"Likewise, clearance values were greater following inhalation, 5532 +/- 1756 ml/min/kg, than following intravenous administration, 163 +/- 20.6 ml/min/kg (p less than 0.04).",Inhalational administration of cocaine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034039/),[ml] / [kg·min],163,98871,DB00907,Cocaine
,30629049,peak plasma concentration,The mean peak plasma concentration was 20.35 micrograms/L occurring at 120 minutes post-administration.,Is atomised intranasal cocaine systemically absorbed during endoscopic sinus surgery? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30629049/),[μg] / [l],20.35,103864,DB00907,Cocaine
,28442345,Kd,"All three antibodies had long elimination half-lives, 2-5 nM Kd for cocaine, and prevented cocaine's entry into the brain by sequestering it in the plasma.",Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442345/),nM,2-5,104789,DB00907,Cocaine
,23649883,α,"Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)).",Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),1/[h],10.23,106059,DB00907,Cocaine
,23649883,β,"Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)).",Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),1/[h],1.86,106060,DB00907,Cocaine
,23649883,absolute bioavailability,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,10,106061,DB00907,Cocaine
,23649883,percentage of,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,21.59,106062,DB00907,Cocaine
,23649883,protein binding,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,21.59,106063,DB00907,Cocaine
,2014157,plasma t1/2,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),min,21,106641,DB00907,Cocaine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],1682,106642,DB00907,Cocaine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],486,106643,DB00907,Cocaine
,31150569,Cmax,The median Cmax for COC in plasma was 379.7 ng/mL (347.5-517.7) and 344.24 ng/mL (271.6-583.2) in whole blood.,"Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],379.7,106762,DB00907,Cocaine
,31150569,Cmax,The median Cmax for COC in plasma was 379.7 ng/mL (347.5-517.7) and 344.24 ng/mL (271.6-583.2) in whole blood.,"Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],344.24,106763,DB00907,Cocaine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],441.2,106764,DB00907,Cocaine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],371.18,106765,DB00907,Cocaine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],105.5,106766,DB00907,Cocaine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],135.5,106767,DB00907,Cocaine
,31150569,whole blood to plasma ratio,"Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),,0.76,106768,DB00907,Cocaine
,31150569,whole blood to plasma ratio,"Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),,0,106769,DB00907,Cocaine
,31150569,whole blood to plasma ratio,"Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),,1,106770,DB00907,Cocaine
,11254184,m/z,The [M+H]+ (m/z=304) and a fragmented ion (m/z=182) were detected using positive ion mode detection.,Determination of free-form of cocaine in rat brain by liquid chromatography-electrospray mass spectrometry with in vivo microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254184/),,304,107346,DB00907,Cocaine
,11254184,m/z,The [M+H]+ (m/z=304) and a fragmented ion (m/z=182) were detected using positive ion mode detection.,Determination of free-form of cocaine in rat brain by liquid chromatography-electrospray mass spectrometry with in vivo microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254184/),,182,107347,DB00907,Cocaine
,17132243,peak concentrations,"Cocaine was detected within 5 min, with mean+/-SE peak concentrations of 300.4+/-24.6 ng/mL (low) and 639.1+/-56.8 ng/mL (high) 30-40 min after dosing.",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],300.4,107456,DB00907,Cocaine
,17132243,peak concentrations,"Cocaine was detected within 5 min, with mean+/-SE peak concentrations of 300.4+/-24.6 ng/mL (low) and 639.1+/-56.8 ng/mL (high) 30-40 min after dosing.",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],639.1,107457,DB00907,Cocaine
,17132243,maximum concentrations,"BE and EME generally were first detected in plasma 5-15 min post-dose; 2-4 h after dosing, BE and EME reached mean maximum concentrations of 321.3+/-18.4 (low) and 614.7+/-46.0 ng/mL (high) and 47.4+/-3.0 (low) and 124.4+/-18.2 ng/mL (high), respectively.",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],321.3,107458,DB00907,Cocaine
,17132243,maximum concentrations,"BE and EME generally were first detected in plasma 5-15 min post-dose; 2-4 h after dosing, BE and EME reached mean maximum concentrations of 321.3+/-18.4 (low) and 614.7+/-46.0 ng/mL (high) and 47.4+/-3.0 (low) and 124.4+/-18.2 ng/mL (high), respectively.",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],614.7,107459,DB00907,Cocaine
,17132243,maximum concentrations,"BE and EME generally were first detected in plasma 5-15 min post-dose; 2-4 h after dosing, BE and EME reached mean maximum concentrations of 321.3+/-18.4 (low) and 614.7+/-46.0 ng/mL (high) and 47.4+/-3.0 (low) and 124.4+/-18.2 ng/mL (high), respectively.",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],47.4,107460,DB00907,Cocaine
,17132243,maximum concentrations,"BE and EME generally were first detected in plasma 5-15 min post-dose; 2-4 h after dosing, BE and EME reached mean maximum concentrations of 321.3+/-18.4 (low) and 614.7+/-46.0 ng/mL (high) and 47.4+/-3.0 (low) and 124.4+/-18.2 ng/mL (high), respectively.",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],124.4,107461,DB00907,Cocaine
<or=,17132243,peak concentrations,"Minor metabolites were detected much less frequently for up to 32 h, with peak concentrations<or=18 ng/mL for all analytes except pOHBE (up to 57.7 ng/mL).",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],18,107462,DB00907,Cocaine
up to,17132243,peak concentrations,"Minor metabolites were detected much less frequently for up to 32 h, with peak concentrations<or=18 ng/mL for all analytes except pOHBE (up to 57.7 ng/mL).",Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132243/),[ng] / [ml],57.7,107463,DB00907,Cocaine
,8745970,Cmax,The Cmax was 859 +/- 503 ng.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),ng,859,108253,DB00907,Cocaine
,8745970,Tmax,mL-1 after a Tmax to 47 +/- 17 min.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,47,108254,DB00907,Cocaine
,8745970,elimination half-life,The mean elimination half-life was 87 +/- 19 min (mean +/- SD).,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,87,108255,DB00907,Cocaine
,8745970,total clearance,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),[ml] / [min],"4,521",108256,DB00907,Cocaine
,8745970,volume of distribution,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),l,568,108257,DB00907,Cocaine
,10022205,half-life,Cocaine had a half-life of 11.6 h in one subject.,Cocaine metabolite kinetics in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10022205/),h,11.6,109228,DB00907,Cocaine
,10022205,half-life,"The half-life of BZE during the first day of life, based on blood data in 13 subjects, was 16 h (95% confidence interval [CI], 12.8 to 21.4 h).",Cocaine metabolite kinetics in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10022205/),h,16,109229,DB00907,Cocaine
,10022205,half-life,"The half-life of BZE during the first week of life, based on urine data in 16 subjects, was 11.2 h (95% CI, 10.1 to 11.8 h).",Cocaine metabolite kinetics in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10022205/),h,11.2,109230,DB00907,Cocaine
,29462364,bioavailability,The mean ± SEM oral cocaine bioavailability was 0.32 ± 0.04 after 100 and 0.45 ± 0.06 after 200 mg oral cocaine.,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),,0.32,110256,DB00907,Cocaine
,29462364,bioavailability,The mean ± SEM oral cocaine bioavailability was 0.32 ± 0.04 after 100 and 0.45 ± 0.06 after 200 mg oral cocaine.,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),,0.45,110257,DB00907,Cocaine
,29462364,Vd,Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]).,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),[l] / [kg],4.2,110258,DB00907,Cocaine
,29462364,CL,Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]).,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),[ml] / [kg·min],116.2,110259,DB00907,Cocaine
,29462364,Vd,Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]).,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),[l] / [kg],2.9,110260,DB00907,Cocaine
,29462364,CL,Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]).,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),[ml] / [kg·min],87.5,110261,DB00907,Cocaine
,29462364,Vd,Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]).,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),[l] / [kg],1.3,110262,DB00907,Cocaine
,29462364,CL,Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]).,Bioavailability and Pharmacokinetics of Oral Cocaine in Humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29462364/),[ml] / [kg·min],32.7,110263,DB00907,Cocaine
,15610940,relative bioavailability,The relative bioavailability of the SR formulation was 55.5% of that of the IR formulation.,"Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15610940/),%,55.5,112172,DB00907,Cocaine
,24574157,LODs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.85,112921,DB00907,Cocaine
,24574157,LODs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.09,112922,DB00907,Cocaine
,24574157,LODs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.34,112923,DB00907,Cocaine
,24574157,LOQs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.09,112924,DB00907,Cocaine
,24574157,LOQs,"Limits of detection and quantification (LODs, LOQs) were 0.85 ng/mL for levamisole and 0.09 ng/mL, and 0.34 ng/mL for aminorex, respectively.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],0.34,112925,DB00907,Cocaine
,24574157,ka,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[1] / [h],1.2,112926,DB00907,Cocaine
,24574157,CL/F,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[l] / [h],52,112927,DB00907,Cocaine
,24574157,V/F,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),l,347,112928,DB00907,Cocaine
,24574157,f (renal),"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),,0.0005,112929,DB00907,Cocaine
,24574157,t ½,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),h,2.0,112930,DB00907,Cocaine
,24574157,AUC,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [h·ml],1923,112931,DB00907,Cocaine
,24574157,cmax,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),[ng] / [ml],214,112932,DB00907,Cocaine
,24574157,tmax,"The following parameters were calculated: ka = 1.2 [1/h], CL/F = 52 l/h, V/F = 347 l, f (renal) = 0.0005, t ½ = 2.0 h, AUC = 1923 ng/mL*h, cmax = 214 ng/mL, tmax = 1.98 h.","Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574157/),h,1.98,112933,DB00907,Cocaine
,10187758,systemic bioavailability,Intragastric alcohol administration significantly increased cocaine systemic bioavailability after ip administration from 0.550 +/- 0.044 to 0. 754 +/- 0.071.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,0.550,114230,DB00907,Cocaine
,10187758,systemic bioavailability,Intragastric alcohol administration significantly increased cocaine systemic bioavailability after ip administration from 0.550 +/- 0.044 to 0. 754 +/- 0.071.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,0. 754,114231,DB00907,Cocaine
,10187758,absorption rate constant,"Also, the absorption rate constant increased from 0. 199 +/- 0.045 to 0.276 +/- 0.059 min-1 due to alcohol coadministration; however, this increase was not significant.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),1/[min],0. 199,114232,DB00907,Cocaine
,10187758,absorption rate constant,"Also, the absorption rate constant increased from 0. 199 +/- 0.045 to 0.276 +/- 0.059 min-1 due to alcohol coadministration; however, this increase was not significant.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),1/[min],0.276,114233,DB00907,Cocaine
,10187758,elimination half-life,Alcohol inhibition of cocaine metabolism caused an increase in cocaine elimination half-life from 26.3 +/- 3.6 to 40.0 +/- 8.1 min.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),min,26.3,114234,DB00907,Cocaine
,10187758,elimination half-life,Alcohol inhibition of cocaine metabolism caused an increase in cocaine elimination half-life from 26.3 +/- 3.6 to 40.0 +/- 8.1 min.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),min,40.0,114235,DB00907,Cocaine
,10187758,Emax,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,850,114236,DB00907,Cocaine
,10187758,Emax,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,1550,114237,DB00907,Cocaine
,10187758,EC50,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),[ng] / [ml],3400,114238,DB00907,Cocaine
,10187758,EC50,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),[ng] / [ml],2000,114239,DB00907,Cocaine
,31642004,C0,The primary PK parameters determined by WinNonlin were a C0 (ng/mL) of 1412.09 ± 196.12 and a plasma half-life of 2.27 ± 0.67 h.,The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642004/),[ng] / [ml],1412.09,114662,DB00907,Cocaine
,31642004,plasma half-life,The primary PK parameters determined by WinNonlin were a C0 (ng/mL) of 1412.09 ± 196.12 and a plasma half-life of 2.27 ± 0.67 h.,The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642004/),h,2.27,114663,DB00907,Cocaine
,27114201,Tlast,"Tlast was generally longer in OF (12.5h cocaine; 33.0h BE) than plasma (9.5h cocaine; >21h BE, cutoffs 1μg/L); 8 and 10μg/L OF cocaine confirmatory cutoffs yielded detection times similar to cocaine's impairing effects, suggesting usefulness for DUID testing.",Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114201/),h,12.5,115907,DB00907,Cocaine
,27114201,Tlast,"Tlast was generally longer in OF (12.5h cocaine; 33.0h BE) than plasma (9.5h cocaine; >21h BE, cutoffs 1μg/L); 8 and 10μg/L OF cocaine confirmatory cutoffs yielded detection times similar to cocaine's impairing effects, suggesting usefulness for DUID testing.",Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114201/),h,33.0,115908,DB00907,Cocaine
,27114201,Tlast,"Tlast was generally longer in OF (12.5h cocaine; 33.0h BE) than plasma (9.5h cocaine; >21h BE, cutoffs 1μg/L); 8 and 10μg/L OF cocaine confirmatory cutoffs yielded detection times similar to cocaine's impairing effects, suggesting usefulness for DUID testing.",Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114201/),h,9.5,115909,DB00907,Cocaine
,27114201,Tlast,"Tlast was generally longer in OF (12.5h cocaine; 33.0h BE) than plasma (9.5h cocaine; >21h BE, cutoffs 1μg/L); 8 and 10μg/L OF cocaine confirmatory cutoffs yielded detection times similar to cocaine's impairing effects, suggesting usefulness for DUID testing.",Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114201/),h,>,115910,DB00907,Cocaine
,27114201,Tlast,"Tlast was generally longer in OF (12.5h cocaine; 33.0h BE) than plasma (9.5h cocaine; >21h BE, cutoffs 1μg/L); 8 and 10μg/L OF cocaine confirmatory cutoffs yielded detection times similar to cocaine's impairing effects, suggesting usefulness for DUID testing.",Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27114201/),h,21,115911,DB00907,Cocaine
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,47,116256,DB00907,Cocaine
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,42,116257,DB00907,Cocaine
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,46,116258,DB00907,Cocaine
,16584286,bioavailability,"The bioavailability of inhaled heroin was estimated to be 53% (95% CI 43.7, 62.3).",Population pharmacokinetics of heroin and its major metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),%,53,116470,DB00907,Cocaine
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,7.6,116471,DB00907,Cocaine
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,21.8,116472,DB00907,Cocaine
,16584286,clearances,"The clearances of morphine and the morphine-glucuronides were estimated to be 73.6 L/h (95% CI 62.8, 84.4) and between 6 and 10 L/h, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),[l] / [h],73.6,116473,DB00907,Cocaine
,8826539,peak plasma cocaine levels,"Male subjects achieved the highest peak plasma cocaine levels (144.4 +/- 17.5 ng/ml), detected cocaine effects significantly faster than females and also experienced a greater number of episodes of intense good and bad effects.",Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826539/),[ng] / [ml],144.4,121525,DB00907,Cocaine
,8826539,peak plasma cocaine levels,"Women studied during the follicular phase of their menstrual cycle had peak plasma cocaine levels of 73.2 +/- 9.9 ng/ml, which was significantly higher than when they were studied during their luteal phase (54.7 +/- 8.7 ng/ml), but there were no differences in their subjective reports of cocaine effects.",Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826539/),[ng] / [ml],73.2,121526,DB00907,Cocaine
,8826539,peak plasma cocaine levels,"Women studied during the follicular phase of their menstrual cycle had peak plasma cocaine levels of 73.2 +/- 9.9 ng/ml, which was significantly higher than when they were studied during their luteal phase (54.7 +/- 8.7 ng/ml), but there were no differences in their subjective reports of cocaine effects.",Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826539/),[ng] / [ml],54.7,121527,DB00907,Cocaine
,3390996,half-life,"The chronotropic effect reached a peak within 10 minutes and then declined, with a half-life of 31 +/- 13 (mean +/- SD) minutes toward a plateau at 33% +/- 21% of its peak intensity.",Acute tolerance to cocaine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3390996/),min,31,121548,DB00907,Cocaine
,9450511,ED50s,"The ED50s (50% occupancy of DAT by cocaine) were 0.27 and 0.17 mg/kg for [11C]d-threo-methylphenidate and [11C]cocaine, respectively.",Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],0.27,121660,DB00907,Cocaine
,9450511,ED50s,"The ED50s (50% occupancy of DAT by cocaine) were 0.27 and 0.17 mg/kg for [11C]d-threo-methylphenidate and [11C]cocaine, respectively.",Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],0.17,121661,DB00907,Cocaine
,9450511,ED50s,This is significantly lower than values obtained with labeled beta-CIT and other similar radiotracers with a slow uptake and clearance (ED50s: 3-7 mg/kg).,Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],3-7,121662,DB00907,Cocaine
,9488509,half-life,"Therefore, due to the relatively long half-life of 18F (109.8 min), PET scans with [18F]CFT could easily be conducted during the binding equilibrium, allowing estimation of Bmax/Kd values (i.e., binding potential).","[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488509/),min,109.8,122234,DB00907,Cocaine
,9488509,Binding potentials,"Binding potentials for putamen and caudate measured at equilibrium were 4.79+/-0.11 and 4.50+/-0.23, respectively.","[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488509/),,4.79,122235,DB00907,Cocaine
,9488509,Binding potentials,"Binding potentials for putamen and caudate measured at equilibrium were 4.79+/-0.11 and 4.50+/-0.23, respectively.","[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488509/),,4.50,122236,DB00907,Cocaine
,7701044,elimination rate constant,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),[l] / [h],0.42,123689,DB00907,Cocaine
,7701044,elimination rate constant,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),[l] / [h],0.67,123690,DB00907,Cocaine
,7701044,elimination half-life,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),h,1.68,123691,DB00907,Cocaine
,7701044,elimination half-life,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),h,1.07,123692,DB00907,Cocaine
,6510853,Excretion,Excretion of benzoylecgonine in urine was 6.3-19.2% in dogs and 7.5-32.9% in rabbits.,In vivo and in vitro studies on cocaine metabolism: ecgonine methyl ester as a major metabolite of cocaine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510853/),%,6.3-19.2,127028,DB00907,Cocaine
,6510853,Excretion,Excretion of benzoylecgonine in urine was 6.3-19.2% in dogs and 7.5-32.9% in rabbits.,In vivo and in vitro studies on cocaine metabolism: ecgonine methyl ester as a major metabolite of cocaine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510853/),%,7.5-32.9,127029,DB00907,Cocaine
,16083654,half-life,The half-life of cocaine in clinical experiments has been reported to range from 60 to 90 min.,Cocaine metabolism in hyperthermic patients with excited delirium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083654/),min,60 to 90,128730,DB00907,Cocaine
,27363313,AUC0→∞,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[h·ng] / [ml],211.5,132038,DB00907,Cocaine
,27363313,AUC0→∞,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[h·ng] / [ml],261.4,132039,DB00907,Cocaine
,27363313,Cmax,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[ng] / [ml],83.3,132040,DB00907,Cocaine
,27363313,Cmax,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[ng] / [ml],104.5,132041,DB00907,Cocaine
,26851651,Cmax,OE observed Cmax median (range) concentrations were 932 (394-1574)μg/L for cocaine and 248 (96.9-953)μg/L for BE.,Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),[μg] / [l],932,134458,DB00907,Cocaine
,26851651,Cmax,OE observed Cmax median (range) concentrations were 932 (394-1574)μg/L for cocaine and 248 (96.9-953)μg/L for BE.,Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),[μg] / [l],248,134459,DB00907,Cocaine
,26851651,Cmax,"SS observed cocaine and BE Cmax median (range) concentrations trended lower at 732 (83.3-1892)μg/L and 360 (77.2-836)μg/L, respectively.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),[μg] / [l],732,134460,DB00907,Cocaine
,26851651,Cmax,"SS observed cocaine and BE Cmax median (range) concentrations trended lower at 732 (83.3-1892)μg/L and 360 (77.2-836)μg/L, respectively.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),[μg] / [l],360,134461,DB00907,Cocaine
,26851651,OF,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,12.5,134462,DB00907,Cocaine
,26851651,OF,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,6.5,134463,DB00907,Cocaine
,26851651,OF,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,30.5,134464,DB00907,Cocaine
,26851651,detection times,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,12.5,134465,DB00907,Cocaine
,26851651,detection times,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,6.5,134466,DB00907,Cocaine
,26851651,detection times,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,30.5,134467,DB00907,Cocaine
,26851651,detection times,"OE and SS cocaine OF detection times were 12.5 and 6.5h and for BE 30.5 and 28.0 h, respectively at 1 μg/L.",Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851651/),h,28.0,134468,DB00907,Cocaine
,10546982,production rate constant,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),[fmol·mg] / [(-1)h],2.36,134522,DB00907,Cocaine
,10546982,degradation rate constant,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),1/[h],0.0077,134523,DB00907,Cocaine
,10546982,half-life of,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),d,3.4,134524,DB00907,Cocaine
,20814350,half-lives,"In oral fluid collected by citric acid candy-stimulated expectoration, cocaine first appeared in oral fluid 0.08 to 0.32 hours after dosing and was rapidly eliminated with half-lives of 1.1 to 3.8 hours.",Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814350/),h,1.1 to 3.8,134766,DB00907,Cocaine
,20814350,half-lives,BE and EME were first detected 0.08 to 1.0 hours after dosing with longer half-lives of 3.4 to 13.8 (BE) and 2.4 to 15.5 hours (EME) (P < 0.05).,Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814350/),h,3.4 to 13.8,134767,DB00907,Cocaine
,20814350,half-lives,BE and EME were first detected 0.08 to 1.0 hours after dosing with longer half-lives of 3.4 to 13.8 (BE) and 2.4 to 15.5 hours (EME) (P < 0.05).,Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814350/),h,2.4 to 15.5,134768,DB00907,Cocaine
,8097710,elimination half-lives (t1/2),"Mean maternal elimination half-lives (t1/2) for cocaine and benzoylecgonine were 1.2 +/- 0.5 hr and 12.4 +/- 6.6 hr (+/- SEM), respectively; fetal half-lives were 0.5 +/- 0.2 and 7.7 +/- 3.0 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,1.2,135604,DB00907,Cocaine
,8097710,elimination half-lives (t1/2),"Mean maternal elimination half-lives (t1/2) for cocaine and benzoylecgonine were 1.2 +/- 0.5 hr and 12.4 +/- 6.6 hr (+/- SEM), respectively; fetal half-lives were 0.5 +/- 0.2 and 7.7 +/- 3.0 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,12.4,135605,DB00907,Cocaine
,8097710,half-lives,"Mean maternal elimination half-lives (t1/2) for cocaine and benzoylecgonine were 1.2 +/- 0.5 hr and 12.4 +/- 6.6 hr (+/- SEM), respectively; fetal half-lives were 0.5 +/- 0.2 and 7.7 +/- 3.0 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,0.5,135606,DB00907,Cocaine
,8097710,half-lives,"Mean maternal elimination half-lives (t1/2) for cocaine and benzoylecgonine were 1.2 +/- 0.5 hr and 12.4 +/- 6.6 hr (+/- SEM), respectively; fetal half-lives were 0.5 +/- 0.2 and 7.7 +/- 3.0 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,7.7,135607,DB00907,Cocaine
,8097710,maternal residence times,"Mean maternal residence times were 1.9 +/- 0.5 and 17.0 +/- 9.1 hr for cocaine and benzoylecgonine, respectively; fetal values were 2.1 +/- 0.2 and 11.6 +/- 3.5 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,1.9,135608,DB00907,Cocaine
,8097710,maternal residence times,"Mean maternal residence times were 1.9 +/- 0.5 and 17.0 +/- 9.1 hr for cocaine and benzoylecgonine, respectively; fetal values were 2.1 +/- 0.2 and 11.6 +/- 3.5 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,17.0,135609,DB00907,Cocaine
,8097710,maternal residence times,"Mean maternal residence times were 1.9 +/- 0.5 and 17.0 +/- 9.1 hr for cocaine and benzoylecgonine, respectively; fetal values were 2.1 +/- 0.2 and 11.6 +/- 3.5 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,2.1,135610,DB00907,Cocaine
,8097710,maternal residence times,"Mean maternal residence times were 1.9 +/- 0.5 and 17.0 +/- 9.1 hr for cocaine and benzoylecgonine, respectively; fetal values were 2.1 +/- 0.2 and 11.6 +/- 3.5 hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,11.6,135611,DB00907,Cocaine
,8097710,Total areas under the concentration versus time curves (AUCs),"Total areas under the concentration versus time curves (AUCs) for cocaine and benzoylecgonine in maternal plasma were 360 +/- 38 and 585 +/- 260 (ng/ml) hr, respectively; fetal values were 104 +/- 29 and 262 +/- 61 (ng/ml) hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,360,135612,DB00907,Cocaine
,8097710,Total areas under the concentration versus time curves (AUCs),"Total areas under the concentration versus time curves (AUCs) for cocaine and benzoylecgonine in maternal plasma were 360 +/- 38 and 585 +/- 260 (ng/ml) hr, respectively; fetal values were 104 +/- 29 and 262 +/- 61 (ng/ml) hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),h,585,135613,DB00907,Cocaine
,8097710,Total areas under the concentration versus time curves (AUCs),"Total areas under the concentration versus time curves (AUCs) for cocaine and benzoylecgonine in maternal plasma were 360 +/- 38 and 585 +/- 260 (ng/ml) hr, respectively; fetal values were 104 +/- 29 and 262 +/- 61 (ng/ml) hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),[ng] / [ml],104,135614,DB00907,Cocaine
,8097710,Total areas under the concentration versus time curves (AUCs),"Total areas under the concentration versus time curves (AUCs) for cocaine and benzoylecgonine in maternal plasma were 360 +/- 38 and 585 +/- 260 (ng/ml) hr, respectively; fetal values were 104 +/- 29 and 262 +/- 61 (ng/ml) hr.",Transplacental pharmacokinetics and maternal/fetal plasma concentrations of cocaine in pregnant macaques near term. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097710/),[ng] / [ml],262,135615,DB00907,Cocaine
,32375158,half-life,"MCAM plasma concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased markedly 1 day after injection.","Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32375158/),min,13.7 to 199.8,138215,DB00907,Cocaine
,7583290,Ed,Results revealed that there was no significant difference of Ed under these three different infusion regimens (group A: 16 +/- 2%; group B: 17 +/- 1%; group C: 21 +/- 2%).,"Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),%,16,143657,DB00907,Cocaine
,7583290,Ed,Results revealed that there was no significant difference of Ed under these three different infusion regimens (group A: 16 +/- 2%; group B: 17 +/- 1%; group C: 21 +/- 2%).,"Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),%,17,143658,DB00907,Cocaine
,7583290,Ed,Results revealed that there was no significant difference of Ed under these three different infusion regimens (group A: 16 +/- 2%; group B: 17 +/- 1%; group C: 21 +/- 2%).,"Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),%,21,143659,DB00907,Cocaine
,7583290,steady-state cocaine concentration,"The steady-state cocaine concentration in the mPFC was also estimated to be 17.7 +/- 1.3 microM, 11.3 +/- 2.0 microM, and 0.7 +/- 0.6 microM, respectively.","Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),μM,17.7,143660,DB00907,Cocaine
,7583290,steady-state cocaine concentration,"The steady-state cocaine concentration in the mPFC was also estimated to be 17.7 +/- 1.3 microM, 11.3 +/- 2.0 microM, and 0.7 +/- 0.6 microM, respectively.","Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),μM,11.3,143661,DB00907,Cocaine
,7583290,steady-state cocaine concentration,"The steady-state cocaine concentration in the mPFC was also estimated to be 17.7 +/- 1.3 microM, 11.3 +/- 2.0 microM, and 0.7 +/- 0.6 microM, respectively.","Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),μM,0.7,143662,DB00907,Cocaine
,7583290,steady-state cocaine concentration,We then concluded that the Ed of cocaine in the mPFC is invariable while the steady-state cocaine concentration in the mPFC was ranging from 0 to 18 microM.,"Determination of microdialysis extraction fraction of cocaine by the no net flux method under high, low, and zero steady-state cocaine concentrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7583290/),μM,0 to 18,143663,DB00907,Cocaine
,11418266,tissue/plasma concentration ratios,"A significantly lower concentration of benzoylecgonine was found in both maternal and fetal brain at 0 h postinfusion, with tissue/plasma concentration ratios of 0.04 and 0.24, respectively, suggesting that benzoylecgonine does not readily penetrate into the brain.",The disposition of benzoylecgonine in maternal and fetal rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418266/),,0.04,144573,DB00907,Cocaine
,11418266,tissue/plasma concentration ratios,"A significantly lower concentration of benzoylecgonine was found in both maternal and fetal brain at 0 h postinfusion, with tissue/plasma concentration ratios of 0.04 and 0.24, respectively, suggesting that benzoylecgonine does not readily penetrate into the brain.",The disposition of benzoylecgonine in maternal and fetal rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418266/),,0.24,144574,DB00907,Cocaine
,25524052,half-life,TV-1380 was found to be safe and well tolerated with a long half-life (43-77 hours) and showed a dose-proportional increase in systemic exposure.,"Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524052/),h,43-77,153004,DB00907,Cocaine
,954975,T 1/2,"After i.v. injections of cocaine, norcocaine, pseudococaine to the rat, the T 1/2 in brain were 0.4, 0.6, 0.2 h respectively and in plasma 0.4, 0.5, 0.2 h respectively.",[3H]-Noncocaine and [3H]-pseudococaine: effect of N-demethylation and C2-epimerization of cocaine on its pharmacokinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954975/),h,0.4,156132,DB00907,Cocaine
,954975,T 1/2,"After i.v. injections of cocaine, norcocaine, pseudococaine to the rat, the T 1/2 in brain were 0.4, 0.6, 0.2 h respectively and in plasma 0.4, 0.5, 0.2 h respectively.",[3H]-Noncocaine and [3H]-pseudococaine: effect of N-demethylation and C2-epimerization of cocaine on its pharmacokinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954975/),h,0.6,156133,DB00907,Cocaine
,954975,T 1/2,"After i.v. injections of cocaine, norcocaine, pseudococaine to the rat, the T 1/2 in brain were 0.4, 0.6, 0.2 h respectively and in plasma 0.4, 0.5, 0.2 h respectively.",[3H]-Noncocaine and [3H]-pseudococaine: effect of N-demethylation and C2-epimerization of cocaine on its pharmacokinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954975/),h,0.2,156134,DB00907,Cocaine
,954975,T 1/2,"After i.v. injections of cocaine, norcocaine, pseudococaine to the rat, the T 1/2 in brain were 0.4, 0.6, 0.2 h respectively and in plasma 0.4, 0.5, 0.2 h respectively.",[3H]-Noncocaine and [3H]-pseudococaine: effect of N-demethylation and C2-epimerization of cocaine on its pharmacokinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954975/),h,0.5,156135,DB00907,Cocaine
,21507153,K(i-High),"In vitro receptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors with K(i-High) (0.68 × 10(-4) nM) and K(i-Low) (2.11 nM), and displays > 150-fold selectivity for D3 over D2 receptors and > 1000-fold selectivity for D3 over other DA receptors.","YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21507153/),nM,0.68 × 10(-4),157373,DB00907,Cocaine
,21507153,K(i-Low),"In vitro receptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors with K(i-High) (0.68 × 10(-4) nM) and K(i-Low) (2.11 nM), and displays > 150-fold selectivity for D3 over D2 receptors and > 1000-fold selectivity for D3 over other DA receptors.","YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21507153/),nM,2.11,157374,DB00907,Cocaine
,12657914,limits of detection,The limits of detection (0.01 microg/mL) and quantitation (0.5 microg/mL) were well below the concentration expected in serum from patients receiving therapeutic doses of modafinil.,Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657914/),[μg] / [ml],0.01,159323,DB00907,Cocaine
,21990608,half-life,Elimination of DM-CocE was quantified by using [³⁵S] labeling of the enzyme and was found to have a half-life of 2.1 h in rats.,"The fate of bacterial cocaine esterase (CocE): an in vivo study of CocE-mediated cocaine hydrolysis, CocE pharmacokinetics, and CocE elimination. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21990608/),h,2.1,159743,DB00907,Cocaine
,2811597,area under the cocaine concentration versus time curve (AUC),The area under the cocaine concentration versus time curve (AUC) in fetus compared to maternal plasma was 3.33.,Tissue distribution of cocaine in the pregnant rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2811597/),,3.33,160908,DB00907,Cocaine
,2811597,half-life,"The half-life of cocaine in the maternal plasma and fetus was 46 and 55 minutes, respectively, similar to values reported for cocaine elimination half-life in human plasma.",Tissue distribution of cocaine in the pregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2811597/),min,46,160909,DB00907,Cocaine
,2811597,half-life,"The half-life of cocaine in the maternal plasma and fetus was 46 and 55 minutes, respectively, similar to values reported for cocaine elimination half-life in human plasma.",Tissue distribution of cocaine in the pregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2811597/),min,55,160910,DB00907,Cocaine
,22406103,elution at flow rate,"The analysis was carried out on an ACQUITY UPLC™ BEH HILIC column (1.7 μm, 2.1 mm×50 mm) with isocratic elution at flow rate of 0.2 mL/min using 10mM ammonium formate in 0.1% formic acid and acetonitrile (10:90) as the mobile phase.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),[ml] / [min],0.2,161605,DB00907,Cocaine
,22406103,run time,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,4,161606,DB00907,Cocaine
,22406103,retention times,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,2.6,161607,DB00907,Cocaine
,22406103,retention times,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,2.1,161608,DB00907,Cocaine
,22406103,recovery,The mean recovery of CM156 from plasma was 96.8%.,"Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),%,96.8,161609,DB00907,Cocaine
,8584615,plasma concentrations,"No differences in plasma concentrations were found 10 min after the administration of a cumulative versus a single dose of cocaine 0.4 mg/kg (mean, 75.8 and 74.0 ng/ml, respectively).",Relationship between the discriminative stimulus effects and plasma concentrations of intramuscular cocaine in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584615/),[ng] / [ml],75.8,163177,DB00907,Cocaine
,8584615,plasma concentrations,"No differences in plasma concentrations were found 10 min after the administration of a cumulative versus a single dose of cocaine 0.4 mg/kg (mean, 75.8 and 74.0 ng/ml, respectively).",Relationship between the discriminative stimulus effects and plasma concentrations of intramuscular cocaine in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584615/),[ng] / [ml],74.0,163178,DB00907,Cocaine
,11599591,recovery,Cocaine recovery was 94.4% and benzoylecgonine was 80.3% at 2.5 ng/mL.,A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599591/),%,94.4,168316,DB00907,Cocaine
,11599591,recovery,Cocaine recovery was 94.4% and benzoylecgonine was 80.3% at 2.5 ng/mL.,A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599591/),%,80.3,168317,DB00907,Cocaine
,8274818,areas under the concentration versus time curve (AUCs,"For the pregnant subjects, pharmacokinetic studies were conducted on about gestational day 125 and areas under the concentration versus time curve (AUCs, ng/mL x h) were 64 +/- 26 (+/- SEM) and 143 +/- 12; half-lives (t1/2s, h) were 1.9 +/- 0.6 and 1.1 +/- 0.1 after 0.3 and 1.0 mg/kg i.m., respectively.",Pharmacokinetics of cocaine in pregnant and nonpregnant rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274818/),[ng] / [h·ml],64,169491,DB00907,Cocaine
,8274818,areas under the concentration versus time curve (AUCs,"For the pregnant subjects, pharmacokinetic studies were conducted on about gestational day 125 and areas under the concentration versus time curve (AUCs, ng/mL x h) were 64 +/- 26 (+/- SEM) and 143 +/- 12; half-lives (t1/2s, h) were 1.9 +/- 0.6 and 1.1 +/- 0.1 after 0.3 and 1.0 mg/kg i.m., respectively.",Pharmacokinetics of cocaine in pregnant and nonpregnant rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274818/),[ng] / [h·ml],143,169492,DB00907,Cocaine
,8274818,half-lives (t1/2s,"For the pregnant subjects, pharmacokinetic studies were conducted on about gestational day 125 and areas under the concentration versus time curve (AUCs, ng/mL x h) were 64 +/- 26 (+/- SEM) and 143 +/- 12; half-lives (t1/2s, h) were 1.9 +/- 0.6 and 1.1 +/- 0.1 after 0.3 and 1.0 mg/kg i.m., respectively.",Pharmacokinetics of cocaine in pregnant and nonpregnant rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274818/),h,1.9,169493,DB00907,Cocaine
,8274818,half-lives (t1/2s,"For the pregnant subjects, pharmacokinetic studies were conducted on about gestational day 125 and areas under the concentration versus time curve (AUCs, ng/mL x h) were 64 +/- 26 (+/- SEM) and 143 +/- 12; half-lives (t1/2s, h) were 1.9 +/- 0.6 and 1.1 +/- 0.1 after 0.3 and 1.0 mg/kg i.m., respectively.",Pharmacokinetics of cocaine in pregnant and nonpregnant rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274818/),h,1.1,169494,DB00907,Cocaine
,8274818,AUC,"For nonpregnant subjects dosed acutely with 1.0 mg/kg, the AUC was 262 +/- 63 and the t1/2 was 1.4 +/- 0.3.",Pharmacokinetics of cocaine in pregnant and nonpregnant rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274818/),,262,169495,DB00907,Cocaine
,8274818,t1/2,"For nonpregnant subjects dosed acutely with 1.0 mg/kg, the AUC was 262 +/- 63 and the t1/2 was 1.4 +/- 0.3.",Pharmacokinetics of cocaine in pregnant and nonpregnant rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274818/),,1.4,169496,DB00907,Cocaine
,11303043,bioavailability,The bioavailability of the orally administered cocaine was calculated as 25%.,Pharmacokinetics of cocaine in maternal and fetal rhesus monkeys at mid-gestation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11303043/),%,25,172815,DB00907,Cocaine
,1356493,T1/2,This is always the case if the research substance can be labelled practically carrier-free with a short-lived positron emitter such as 11C (T1/2 = 20 min) or if applicable 18F (T1/2 = 110 min).,[Applications of positron emission tomography (PET) to the measurement of regional cerebral pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356493/),min,20,173031,DB00907,Cocaine
,1356493,T1/2,This is always the case if the research substance can be labelled practically carrier-free with a short-lived positron emitter such as 11C (T1/2 = 20 min) or if applicable 18F (T1/2 = 110 min).,[Applications of positron emission tomography (PET) to the measurement of regional cerebral pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356493/),min,110,173032,DB00907,Cocaine
,8796829,clearance rate,"Fetal-placental cocaine clearance rate was independent of dose (337 +/- 39 mL/kg/minute), indicating that it is a first-order pharmacokinetic process.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[ml] / [kg·min],337,173366,DB00907,Cocaine
,8796829,heart rate,"There were significant increases in fetal heart rate (from 169 +/- 11 to 242 +/- 36 beats per minute), mean blood pressure (from 53 +/- 4 to 63 +/- 5 mmHg), and systolic blood pressure (from 68 +/- 2 to 80 +/- 5 mmHg), with a corresponding increase in catecholamine levels seen in the fetuses infused with 0.2 mg/kg/minute.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[beats] / [min],169,173367,DB00907,Cocaine
,8796829,heart rate,"There were significant increases in fetal heart rate (from 169 +/- 11 to 242 +/- 36 beats per minute), mean blood pressure (from 53 +/- 4 to 63 +/- 5 mmHg), and systolic blood pressure (from 68 +/- 2 to 80 +/- 5 mmHg), with a corresponding increase in catecholamine levels seen in the fetuses infused with 0.2 mg/kg/minute.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[beats] / [min],242,173368,DB00907,Cocaine
,11854142,C(max),"Although the C(max) for the 1-mg/kg unit dose (1.47 microg/ml) was significantly higher than that for the 0.5-mg/kg dose (0.82 microg/ml), the C(min) values between the groups approximated each other (0.28, and 0.34 microg/ml, respectively).",The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854142/),[μg] / [ml],1.47,174639,DB00907,Cocaine
,11854142,C(max),"Although the C(max) for the 1-mg/kg unit dose (1.47 microg/ml) was significantly higher than that for the 0.5-mg/kg dose (0.82 microg/ml), the C(min) values between the groups approximated each other (0.28, and 0.34 microg/ml, respectively).",The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854142/),[μg] / [ml],0.82,174640,DB00907,Cocaine
,11854142,C(min),"Although the C(max) for the 1-mg/kg unit dose (1.47 microg/ml) was significantly higher than that for the 0.5-mg/kg dose (0.82 microg/ml), the C(min) values between the groups approximated each other (0.28, and 0.34 microg/ml, respectively).",The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854142/),[μg] / [ml],0.28,174641,DB00907,Cocaine
,11854142,C(min),"Although the C(max) for the 1-mg/kg unit dose (1.47 microg/ml) was significantly higher than that for the 0.5-mg/kg dose (0.82 microg/ml), the C(min) values between the groups approximated each other (0.28, and 0.34 microg/ml, respectively).",The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854142/),[μg] / [ml],0.34,174642,DB00907,Cocaine
,9210433,detection limit,The detection limit was 2.5 ng/ml for all the compounds using an ultraviolet detector operated at 235 nm.,Determination of cocaine and its metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210433/),[ng] / [ml],2.5,175614,DB00907,Cocaine
,19933255,observed maximal concentration,"Massive concentrations of cocaine (observed maximal concentration: 1.66 mg/L, 1 hour after the cardiac arrest) were measured in plasma up to about 15 hours, suggesting a prolonged absorption due to a slow-release in the gastrointestinal tract despite surgical extraction of the packets.",Blood cocaine and metabolite pharmacokinetics after cardiac arrest in a body-packer case. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19933255/),[mg] / [l],1.66,176281,DB00907,Cocaine
,19933255,Apparent cocaine elimination half-life,Apparent cocaine elimination half-life was 7.6 hours.,Blood cocaine and metabolite pharmacokinetics after cardiac arrest in a body-packer case. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19933255/),h,7.6,176282,DB00907,Cocaine
,15967428,plasma half-life,"Butyrylcholinesterase significantly increased plasma and brain ecgonine methylester levels and decreased cocaine plasma half-life from 26.2 min (saline) to 16.4 min (15,000 U).",Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15967428/),min,26.2,177109,DB00907,Cocaine
,15967428,plasma half-life,"Butyrylcholinesterase significantly increased plasma and brain ecgonine methylester levels and decreased cocaine plasma half-life from 26.2 min (saline) to 16.4 min (15,000 U).",Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15967428/),min,16.4,177110,DB00907,Cocaine
,29556863,biological half-life,"However, the therapeutic effects of CocH are limited by its short biological half-life (e.g., 8 h or shorter in rats).",Development of Fc-Fused Cocaine Hydrolase for Cocaine Addiction Treatment: Catalytic and Pharmacokinetic Properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556863/),h,8,178420,DB00907,Cocaine
∼,29556863,biological half-life,"It has been concluded that Fc(M3)-G6S-CocH3 not only has fully retained the catalytic efficiency of CocH3 against cocaine but also has the longest biological half-life (e.g., ∼ 136 h in rats) among all of the long-acting CocHs identified so far.",Development of Fc-Fused Cocaine Hydrolase for Cocaine Addiction Treatment: Catalytic and Pharmacokinetic Properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556863/),h,136,178421,DB00907,Cocaine
,11043648,limit of detection,The limit of detection for each analyte was approximately 1 ng/mL.,"Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043648/),[ng] / [ml],1,178975,DB00907,Cocaine
,11043648,elimination half-lives,"The mean (N = 6) plasma, saliva, and urine cocaine elimination half-lives were 1.5 +/- 0.1 h, 1.2 +/- 0.2 h, and 4.1 +/- 0.9 h, respectively.","Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043648/),h,1.5,178976,DB00907,Cocaine
,11043648,elimination half-lives,"The mean (N = 6) plasma, saliva, and urine cocaine elimination half-lives were 1.5 +/- 0.1 h, 1.2 +/- 0.2 h, and 4.1 +/- 0.9 h, respectively.","Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043648/),h,1.2,178977,DB00907,Cocaine
,11043648,elimination half-lives,"The mean (N = 6) plasma, saliva, and urine cocaine elimination half-lives were 1.5 +/- 0.1 h, 1.2 +/- 0.2 h, and 4.1 +/- 0.9 h, respectively.","Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043648/),h,4.1,178978,DB00907,Cocaine
,11043648,urinary elimination half-life,"For three subjects, the mean cocaine urinary elimination half-life for the terminal phase was 19.0 +/- 4.2 h.","Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043648/),h,19.0,178979,DB00907,Cocaine
,11043648,half-life,A terminal elimination phase was also observed for cocaine metabolites with half-life estimates ranging from 14.6 to 52.4 h.,"Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043648/),h,14.6 to 52.4,178980,DB00907,Cocaine
,9215969,Limits of detection (LOD),"Limits of detection (LOD) were 1.0 and 2.0 ng ml-1 for cocaine and cocaethylene, respectively.",Quantitation of cocaine and cocaethylene in small volumes of rat whole blood using gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215969/),[ng] / [ml],1.0,182632,DB00907,Cocaine
,9215969,Limits of detection (LOD),"Limits of detection (LOD) were 1.0 and 2.0 ng ml-1 for cocaine and cocaethylene, respectively.",Quantitation of cocaine and cocaethylene in small volumes of rat whole blood using gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215969/),[ng] / [ml],2.0,182633,DB00907,Cocaine
,9088006,peak plasma concentrations,"Mean +/- SEM peak plasma concentrations of cocaine occurred at 30 s in a dose-response manner (370 +/- 14,755 +/- 119,2553 +/- 898 ng/ml for 0.5, 1.0, and 3.0 mg/kg groups, respectively).","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[ng] / [ml],370,183519,DB00907,Cocaine
,9088006,peak plasma concentrations,"Mean +/- SEM peak plasma concentrations of cocaine occurred at 30 s in a dose-response manner (370 +/- 14,755 +/- 119,2553 +/- 898 ng/ml for 0.5, 1.0, and 3.0 mg/kg groups, respectively).","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[ng] / [ml],755,183520,DB00907,Cocaine
,9088006,peak plasma concentrations,"Mean +/- SEM peak plasma concentrations of cocaine occurred at 30 s in a dose-response manner (370 +/- 14,755 +/- 119,2553 +/- 898 ng/ml for 0.5, 1.0, and 3.0 mg/kg groups, respectively).","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[ng] / [ml],2553,183521,DB00907,Cocaine
<,9088006,T1/2 alpha,"T1/2 alpha was < 1 min for all groups, but inversely related to dose.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,1,183522,DB00907,Cocaine
,9088006,T1/2 beta,"T1/2 beta was independent of dose 13.3 +/- 1.6, 13.0 +/- 1.5, and 12.0 +/- 2.0 min for 0.5, 1.0, and 3.0 mg/kg groups, respectively).","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,13.3,183523,DB00907,Cocaine
,9088006,T1/2 beta,"T1/2 beta was independent of dose 13.3 +/- 1.6, 13.0 +/- 1.5, and 12.0 +/- 2.0 min for 0.5, 1.0, and 3.0 mg/kg groups, respectively).","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,13.0,183524,DB00907,Cocaine
,9088006,T1/2 beta,"T1/2 beta was independent of dose 13.3 +/- 1.6, 13.0 +/- 1.5, and 12.0 +/- 2.0 min for 0.5, 1.0, and 3.0 mg/kg groups, respectively).","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,12.0,183525,DB00907,Cocaine
,9088006,MRT,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,16.0,183526,DB00907,Cocaine
,9088006,MRT,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,15.9,183527,DB00907,Cocaine
,9088006,MRT,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),min,14.5,183528,DB00907,Cocaine
,9088006,VdSS,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[l] / [kg],3.3,183529,DB00907,Cocaine
,9088006,VdSS,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[l] / [kg],3.2,183530,DB00907,Cocaine
,9088006,VdSS,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[l] / [kg],2.8,183531,DB00907,Cocaine
,9088006,ClTOT,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[ml] / [kg·min],204,183532,DB00907,Cocaine
,9088006,ClTOT,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[ml] / [kg·min],201,183533,DB00907,Cocaine
,9088006,ClTOT,"MRT (16.0, 15.9, 14.5 min), VdSS (3.3, 3.2, and 2.8 l/kg), and ClTOT (204, 201, and 195 ml/min/kg) also provided little evidence of dose-dependent effects.","Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088006/),[ml] / [kg·min],195,183534,DB00907,Cocaine
,19482449,half-life,The median half-life of cocaine in hair was 1.5 months (95% CI 1.2-1.8) in females and 1.5 months (95% CI 1.1-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183710,DB00907,Cocaine
,19482449,half-life,The median half-life of cocaine in hair was 1.5 months (95% CI 1.2-1.8) in females and 1.5 months (95% CI 1.1-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183711,DB00907,Cocaine
,19482449,half-life,The median half-life of BE was 1.5 months (95% CI 1.1-2) in females and 1.5 months (95% CI 0.8-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183712,DB00907,Cocaine
,19482449,half-life,The median half-life of BE was 1.5 months (95% CI 1.1-2) in females and 1.5 months (95% CI 0.8-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183713,DB00907,Cocaine
over,19482449,half-life,"The calculated half-life of over 1 month for cocaine implies that, assuming first order elimination, approximately 3-4 months have to pass for hair testing to become negative in the segment proximal to the scalp.",Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1,183714,DB00907,Cocaine
,1435082,half-life,The disappearance of cocaine (1 mg/kg) from the plasma exhibited first order kinetics with a half-life of 18.11 +/- 3.22 min.,The presence of cocaine and benzoylecgonine in rat cerebrospinal fluid after the intravenous administration of cocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435082/),min,18.11,184350,DB00907,Cocaine
,3585721,Vd,"The pharmacokinetic parameters of cocaine in sheep had mean values of 4.0 L/kg, 3.5 L/kg, and 0.29 L X min-1 X kg-1 for Vd, Vdss, and CL respectively.",Determination of pharmacokinetics of cocaine in sheep by liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3585721/),[l] / [kg],4.0,184969,DB00907,Cocaine
,3585721,Vd,"The pharmacokinetic parameters of cocaine in sheep had mean values of 4.0 L/kg, 3.5 L/kg, and 0.29 L X min-1 X kg-1 for Vd, Vdss, and CL respectively.",Determination of pharmacokinetics of cocaine in sheep by liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3585721/),[l] / [kg],3.5,184970,DB00907,Cocaine
,3585721,Vdss,"The pharmacokinetic parameters of cocaine in sheep had mean values of 4.0 L/kg, 3.5 L/kg, and 0.29 L X min-1 X kg-1 for Vd, Vdss, and CL respectively.",Determination of pharmacokinetics of cocaine in sheep by liquid chromatography. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3585721/),[l] / [kg],3.5,184971,DB00907,Cocaine
,3585721,Vd,"The pharmacokinetic parameters of cocaine in sheep had mean values of 4.0 L/kg, 3.5 L/kg, and 0.29 L X min-1 X kg-1 for Vd, Vdss, and CL respectively.",Determination of pharmacokinetics of cocaine in sheep by liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3585721/),[l] / [kg·min],0.29,184972,DB00907,Cocaine
,3585721,Vdss,"The pharmacokinetic parameters of cocaine in sheep had mean values of 4.0 L/kg, 3.5 L/kg, and 0.29 L X min-1 X kg-1 for Vd, Vdss, and CL respectively.",Determination of pharmacokinetics of cocaine in sheep by liquid chromatography. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3585721/),[l] / [kg·min],0.29,184973,DB00907,Cocaine
,3585721,CL,"The pharmacokinetic parameters of cocaine in sheep had mean values of 4.0 L/kg, 3.5 L/kg, and 0.29 L X min-1 X kg-1 for Vd, Vdss, and CL respectively.",Determination of pharmacokinetics of cocaine in sheep by liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3585721/),[l] / [kg·min],0.29,184974,DB00907,Cocaine
,16586462,V(dss),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [kg],18.7,187473,DB00907,Cocaine
,16586462,Cl,"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [h·kg],1.8,187474,DB00907,Cocaine
,16586462,t(1/2),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,7.69,187475,DB00907,Cocaine
,16586462,V(dss),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [kg],17.4,187476,DB00907,Cocaine
,16586462,Cl,"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [h·kg],1.9,187477,DB00907,Cocaine
,16586462,t(1/2),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,6.82,187478,DB00907,Cocaine
,16586462,B/P,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),,4.8,187479,DB00907,Cocaine
,16586462,B/P,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),,4.4,187480,DB00907,Cocaine
,16586462,half-lives (t(1/2,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,6.2,187481,DB00907,Cocaine
,16586462,t(1/2,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,5.6,187482,DB00907,Cocaine
,20228156,elimination half-lives,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),h,1.49 to 3.27,187646,DB00907,Cocaine
,20228156,volumes of distribution,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),[l] / [kg],5.95-14.19,187647,DB00907,Cocaine
,20228156,brain-to-plasma ratios,The brain-to-plasma ratios ranged from 2.93 to 11.81 and were higher than those previously reported for cocaine.,"Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),,2.93 to 11.81,187648,DB00907,Cocaine
,19653786,Cmax,The dosing regimen produced cocaine plasma concentrations (Cmax of 680 ng/mL) two to threefold higher than typically seen in acute dose studies.,"Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653786/),[ng] / [ml],680,189868,DB00907,Cocaine
,4028628,steady-state volume of distribution,"The steady-state volume of distribution averaged 131.8 L or 1.96 L/kg, elimination clearance was 2.10 L/min, and the t 1/2 was 48 minutes.","Kinetics of cocaine distribution, elimination, and chronotropic effects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028628/),l,131.8,190255,DB00907,Cocaine
,4028628,steady-state volume of distribution,"The steady-state volume of distribution averaged 131.8 L or 1.96 L/kg, elimination clearance was 2.10 L/min, and the t 1/2 was 48 minutes.","Kinetics of cocaine distribution, elimination, and chronotropic effects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028628/),[l] / [kg],1.96,190256,DB00907,Cocaine
,4028628,elimination clearance,"The steady-state volume of distribution averaged 131.8 L or 1.96 L/kg, elimination clearance was 2.10 L/min, and the t 1/2 was 48 minutes.","Kinetics of cocaine distribution, elimination, and chronotropic effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028628/),[l] / [min],2.10,190257,DB00907,Cocaine
,4028628,t 1/2,"The steady-state volume of distribution averaged 131.8 L or 1.96 L/kg, elimination clearance was 2.10 L/min, and the t 1/2 was 48 minutes.","Kinetics of cocaine distribution, elimination, and chronotropic effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028628/),min,48,190258,DB00907,Cocaine
,9450505,clearance,Cocaine clearance was dose-dependent with clearance decreasing from 1.53 +/- 0.31 to 1.09 +/- 0.11 l/min as the dose was increased from 1 to 5 mg/kg (p<0.05).,Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [min],1.53,192600,DB00907,Cocaine
,9450505,clearance,Cocaine clearance was dose-dependent with clearance decreasing from 1.53 +/- 0.31 to 1.09 +/- 0.11 l/min as the dose was increased from 1 to 5 mg/kg (p<0.05).,Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [min],1.09,192601,DB00907,Cocaine
,9450505,Vmax x Vss,"Vmax x Vss and Km for cocaine were 0.95 +/- 0.40 l/min/kg and 11.2 +/- 6.2 mg/kg, respectively.",Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [kg·min],0.95,192602,DB00907,Cocaine
,9450505,Km,"Vmax x Vss and Km for cocaine were 0.95 +/- 0.40 l/min/kg and 11.2 +/- 6.2 mg/kg, respectively.",Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[mg] / [kg],11.2,192603,DB00907,Cocaine
,10482802,satiety threshold,"The mathematical model generated mean values for the satiety threshold and the functional elimination half-life of cocaine of approximately 1.7 mg/kg (i.v.) and 8.2 min, respectively.",Satiety threshold: a quantitative model of maintained cocaine self-administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10482802/),[mg] / [kg],1.7,192700,DB00907,Cocaine
,10482802,functional elimination half-life,"The mathematical model generated mean values for the satiety threshold and the functional elimination half-life of cocaine of approximately 1.7 mg/kg (i.v.) and 8.2 min, respectively.",Satiety threshold: a quantitative model of maintained cocaine self-administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10482802/),min,8.2,192701,DB00907,Cocaine
,10482802,elimination rate,The elimination rate of cocaine at the satiety threshold was calculated to be approximately 2 microg kg(-1) s(-1).,Satiety threshold: a quantitative model of maintained cocaine self-administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10482802/),[μg] / [kg·s],2,192702,DB00907,Cocaine
,7892416,relative systemic bioavailability,Comparison of dose corrected areas under the curve of the two routes of administration for each drug indicated that relative systemic bioavailability of cocaethylene following intraperitoneal administration is only 58% that of cocaine.,Differences in bioavailability between cocaine and cocaethylene and their implications for drug-reward studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7892416/),%,58,193589,DB00907,Cocaine
,3668848,brain to plasma ratios,The opposite was true for the concentrations of benzoylecgonine; brain to plasma ratios of benzoylecgonine were approximately 0.1 from 5 to 30 min after i.p. cocaine injection.,Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668848/),,0.1,194596,DB00907,Cocaine
,3668848,half-life,"After i.p. injection of either 10 or 25 mg/kg of cocaine, cocaine disappeared from plasma and brain with a half-life of 16 min and benzoylecgonine disappeared from plasma with a half-life of 62 min.",Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668848/),min,16,194597,DB00907,Cocaine
,3668848,half-life,"After i.p. injection of either 10 or 25 mg/kg of cocaine, cocaine disappeared from plasma and brain with a half-life of 16 min and benzoylecgonine disappeared from plasma with a half-life of 62 min.",Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668848/),min,62,194598,DB00907,Cocaine
,12394422,K(D),"Animals were trained to discriminate 5 or 10 mg/kg cocaine (rats), or 3 mg/kg (+)-amphetamine (pigeons) from saline, after which dose-response curves were determined for (+)-methamphetamine and other drugs before and after administration of a (+)-methamphetamine-specific monoclonal antibody (K(D) =250 nM).",Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394422/),nM,250,198525,DB00907,Cocaine
,12966155,Transport,Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[cm] / [s],2.15 x 10-4,200743,DB00907,Cocaine
,12966155,Transport,Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[cm] / [s],2.83 x 10-4,200744,DB00907,Cocaine
,12966155,Transport,Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[cm] / [s],1.63 x 10-4,200745,DB00907,Cocaine
,12966155,volume of distribution,The volume of distribution (12.3-30.5 l/kg) of the analogs was significantly higher than cocaine (0.9 l/kg).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[l] / [kg],12.3-30.5,200746,DB00907,Cocaine
,12966155,volume of distribution,The volume of distribution (12.3-30.5 l/kg) of the analogs was significantly higher than cocaine (0.9 l/kg).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[l] / [kg],0.9,200747,DB00907,Cocaine
,12966155,elimination half-life,The BZT analogs displayed a > or =8-fold higher elimination half-life (4.12-16.49 h) compared with cocaine (0.49 h).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),h,4.12-16.49,200748,DB00907,Cocaine
,12966155,elimination half-life,The BZT analogs displayed a > or =8-fold higher elimination half-life (4.12-16.49 h) compared with cocaine (0.49 h).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),h,0.49,200749,DB00907,Cocaine
,11043750,detection limit,"The detection limit (0.5 ng/ml) for all the compounds, using direct fluorometric detection operated at excitation and emission wavelengths of 230 and 315 nm, respectively, was approximately five-times lower than that of using a UV detector operated at 235 nm.",High-performance liquid chromatographic determination of cocaine and its metabolites in serum microsamples with fluorimetric detection and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043750/),[ng] / [ml],0.5,201558,DB00907,Cocaine
,15999148,half-life,"Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h).",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),h,3,202858,DB00907,Cocaine
,15999148,half-life,"Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h).",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),h,6-9,202859,DB00907,Cocaine
,15999148,plasma ratio,"MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5 / 100, similar to that in humans.",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),,3-5,202860,DB00907,Cocaine
,30634109,ED50,The ED50 for MDPV-induced locomotor was significantly lower in males (2.4 ± 0.3) than females (3.4 ± 0.2).,"Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30634109/),,2.4,204039,DB00907,Cocaine
,30634109,ED50,The ED50 for MDPV-induced locomotor was significantly lower in males (2.4 ± 0.3) than females (3.4 ± 0.2).,"Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30634109/),,3.4,204040,DB00907,Cocaine
,10954344,systemic bioavailability,The median systemic bioavailability after oral dosing was 33%.,Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954344/),%,33,204889,DB00907,Cocaine
,10954344,fraction absorbed through,The fraction absorbed through the nasal mucosa was estimated to be 19% (95% CI: 11-26%).,Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954344/),%,19,204890,DB00907,Cocaine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],3.8,205627,DB00907,Cocaine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],2.5,205628,DB00907,Cocaine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,3.3,205629,DB00907,Cocaine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,5.9,205630,DB00907,Cocaine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],1.5,205631,DB00907,Cocaine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],2.1,205632,DB00907,Cocaine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,26.3,205633,DB00907,Cocaine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,25.0,205634,DB00907,Cocaine
,10454044,systemic clearances,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[ml] / [kg·min],146,205635,DB00907,Cocaine
,32332467,half-life,Ketamine (K) is used as a party drug with hallucinogenic properties with a half-life of about 2.5 hours.,Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),h,2.5,210256,DB00907,Cocaine
,32332467,peak detection period,"A peak detection period of 61, 40, and 96 days for K, norketamine, and dehydronorketamine, respectively, measured using liquid chromatography-tandem mass spectrometry at a cutoff concentration of 1.0 ng/mL, is defined.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),d,61,210257,DB00907,Cocaine
,32332467,peak detection period,"A peak detection period of 61, 40, and 96 days for K, norketamine, and dehydronorketamine, respectively, measured using liquid chromatography-tandem mass spectrometry at a cutoff concentration of 1.0 ng/mL, is defined.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),d,40,210258,DB00907,Cocaine
,32332467,peak detection period,"A peak detection period of 61, 40, and 96 days for K, norketamine, and dehydronorketamine, respectively, measured using liquid chromatography-tandem mass spectrometry at a cutoff concentration of 1.0 ng/mL, is defined.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),d,96,210259,DB00907,Cocaine
,32332467,K/norketamine,"The K/norketamine and K/dehydronorketamine ratios varied over time between 0.33 and 3.06, and 0.01 and 0.36 for all patients, respectively, implying a large interindividual variation in K metabolism.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),,0,210260,DB00907,Cocaine
,32332467,K/dehydronorketamine,"The K/norketamine and K/dehydronorketamine ratios varied over time between 0.33 and 3.06, and 0.01 and 0.36 for all patients, respectively, implying a large interindividual variation in K metabolism.",Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case Series. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32332467/),,0,210261,DB00907,Cocaine
,26794682,tmax,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,10-12,213346,DB00907,Cocaine
,26794682,elimination (t1/2,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,47-77,213347,DB00907,Cocaine
,26253621,elimination half-life,The elimination half-life in the striatum (61 min) correlates with the decrease in the psychostimulant effect after 60 min.,Concentrations of MDPV in rat striatum correlate with the psychostimulant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253621/),min,61,217024,DB00907,Cocaine
,7603638,total body clearance,"After a single i.v. dose of 2-12 mg/kg, the average +/- SD total body clearance of COC was 59 +/- 16 ml/min/kg and was not dose dependent.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),[ml] / [kg·min],59,218384,DB00907,Cocaine
,7603638,volume of distribution,"However, volume of distribution was 2.1 and 3.9 l/kg, mean resident time (MRT) was 42 and 57 min, and elimination half-life was 34 and 49 min at the 2 and 4 mg/kg dose of COC, respectively.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),[l] / [kg],2.1,218385,DB00907,Cocaine
,7603638,volume of distribution,"However, volume of distribution was 2.1 and 3.9 l/kg, mean resident time (MRT) was 42 and 57 min, and elimination half-life was 34 and 49 min at the 2 and 4 mg/kg dose of COC, respectively.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),[l] / [kg],3.9,218386,DB00907,Cocaine
,7603638,resident time (MRT),"However, volume of distribution was 2.1 and 3.9 l/kg, mean resident time (MRT) was 42 and 57 min, and elimination half-life was 34 and 49 min at the 2 and 4 mg/kg dose of COC, respectively.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),min,42,218387,DB00907,Cocaine
,7603638,resident time (MRT),"However, volume of distribution was 2.1 and 3.9 l/kg, mean resident time (MRT) was 42 and 57 min, and elimination half-life was 34 and 49 min at the 2 and 4 mg/kg dose of COC, respectively.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),min,57,218388,DB00907,Cocaine
,7603638,elimination half-life,"However, volume of distribution was 2.1 and 3.9 l/kg, mean resident time (MRT) was 42 and 57 min, and elimination half-life was 34 and 49 min at the 2 and 4 mg/kg dose of COC, respectively.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),min,34,218389,DB00907,Cocaine
,7603638,elimination half-life,"However, volume of distribution was 2.1 and 3.9 l/kg, mean resident time (MRT) was 42 and 57 min, and elimination half-life was 34 and 49 min at the 2 and 4 mg/kg dose of COC, respectively.",Pharmacokinetics and metabolism of cocaine in maternal and fetal guinea pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603638/),min,49,218390,DB00907,Cocaine
,12208028,peak concentration,"Resultant plasma concentrations varied from 21 to 295 ng/ml, with an average peak concentration of 178 ng/ml observed between 2 and 4h after administration.","Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12208028/),[ng] / [ml],178,221640,DB00907,Cocaine
,28192759,flow rate,A gradient elution was employed with a mobile phase consisting of 5mM potassium phosphate containing 0.1% triethylamine (pH=6.5) (A) and acetonitrile (B) with a flow rate of 1mL/min.,Precise simultaneous quantification of methadone and cocaine in rat serum and brain tissue samples following their successive i.p. administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28192759/),[ml] / [min],1,222494,DB00907,Cocaine
,8637393,half-life,"kg-1, is rapidly eliminated with a half-life of 29 min and a total body clearance of 77 ml.",In vivo pharmacokinetics and in vitro production of cocaethylene in pregnant guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8637393/),min,29,223430,DB00907,Cocaine
,8637393,total body clearance,"kg-1, is rapidly eliminated with a half-life of 29 min and a total body clearance of 77 ml.",In vivo pharmacokinetics and in vitro production of cocaethylene in pregnant guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8637393/),ml,77,223431,DB00907,Cocaine
,8637393,apparent Vmax,"The rapid elimination of cocaethylene, coupled with the slow rate of formation (apparent Vmax of 140 pmol.min-1.mg microsomal protein-1) and the small amount of plasma analyzed most likely explains the inability to detect coacethylene in vivo after concomitant cocaine and ethanol administration.",In vivo pharmacokinetics and in vitro production of cocaethylene in pregnant guinea pigs. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8637393/),[mg·pM] / [min],140,223432,DB00907,Cocaine
,2136125,peak plasma level,Sixty mg/kg produced a peak plasma level of 5384 +/- 594 ng/ml in the dam and 2966 +/- 503 ng/ml in the fetus.,Fetal and maternal cocaine levels peak rapidly following intragastric administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136125/),[ng] / [ml],5384,223761,DB00907,Cocaine
,2136125,peak plasma level,Sixty mg/kg produced a peak plasma level of 5384 +/- 594 ng/ml in the dam and 2966 +/- 503 ng/ml in the fetus.,Fetal and maternal cocaine levels peak rapidly following intragastric administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2136125/),[ng] / [ml],2966,223762,DB00907,Cocaine
,11502725,absolute bioavailability,"For oral cocaine, the absolute bioavailability was 3.48%, whereas 6.04 and 2.26% of cocaine were converted to benzoylecgonine and norcocaine, respectively, during first-pass absorption regardless of dose.","Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502725/),%,3.48,225111,DB00907,Cocaine
,11502725,absolute bioavailability,"For oral cocaine, the absolute bioavailability was 3.48%, whereas 6.04 and 2.26% of cocaine were converted to benzoylecgonine and norcocaine, respectively, during first-pass absorption regardless of dose.","Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502725/),%,6.04,225112,DB00907,Cocaine
,11502725,absolute bioavailability,"For oral cocaine, the absolute bioavailability was 3.48%, whereas 6.04 and 2.26% of cocaine were converted to benzoylecgonine and norcocaine, respectively, during first-pass absorption regardless of dose.","Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502725/),%,2.26,225113,DB00907,Cocaine
,8358345,specific activity,The labeled product was prepared in 65.2 +/- 2.8% yield (mean +/- SEM; n = 18) by reaction of the tributylstannyl precursor with [123I]NaI in the presence of peracetic acid followed by high pressure liquid chromatography (HPLC) purification to give a product with radiochemical purity of 97.5 +/- 0.5% and specific activity of 500-1200 Ci/mmol.,"Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[ci] / [mM],500-1200,225231,DB00907,Cocaine
,8358345,clearance half-lives,"After intravenous administration, whole brain activity peaked at 6-10% injected dose within 1 h post injection (p.i.) and washed out in a biphasic manner with clearance half-lives of 1-2 and 7-35 h for the rapid and slow components, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),h,1-2,225232,DB00907,Cocaine
,8358345,clearance half-lives,"After intravenous administration, whole brain activity peaked at 6-10% injected dose within 1 h post injection (p.i.) and washed out in a biphasic manner with clearance half-lives of 1-2 and 7-35 h for the rapid and slow components, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),h,7-35,225233,DB00907,Cocaine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.01,225234,DB00907,Cocaine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.1,225235,DB00907,Cocaine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.2,225236,DB00907,Cocaine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.03,225237,DB00907,Cocaine
,8358345,plasma protein bound fraction,"The plasma protein bound fraction, determined by ultrafiltration, was 74.8 +/- 1.4% (n = 6).","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),%,74.8,225238,DB00907,Cocaine
,8358345,half-lives,"The arterial input function was characterized by the sum of three exponential terms with half-lives of 0.3-1.7, 9.7-24.9 and 77-166 min, respectively, for the concentration of free parent compound.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),min,0.3-1.7,225239,DB00907,Cocaine
,8358345,half-lives,"The arterial input function was characterized by the sum of three exponential terms with half-lives of 0.3-1.7, 9.7-24.9 and 77-166 min, respectively, for the concentration of free parent compound.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),min,9.7-24.9,225240,DB00907,Cocaine
,8358345,half-lives,"The arterial input function was characterized by the sum of three exponential terms with half-lives of 0.3-1.7, 9.7-24.9 and 77-166 min, respectively, for the concentration of free parent compound.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),min,77-166,225241,DB00907,Cocaine
,10503947,elimination half-lives,"The elimination half-lives of cocaine and norcocaine were similar (28-33 min), that for ecgonine methylester (60-71 min) was approximately twice this and for benzoylecgonine was 40-44 min.","Cocaine, norcocaine, ecgonine methylester and benzoylecgonine pharmacokinetics in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10503947/),min,28-33,226027,DB00907,Cocaine
,10503947,elimination half-lives,"The elimination half-lives of cocaine and norcocaine were similar (28-33 min), that for ecgonine methylester (60-71 min) was approximately twice this and for benzoylecgonine was 40-44 min.","Cocaine, norcocaine, ecgonine methylester and benzoylecgonine pharmacokinetics in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10503947/),min,60-71,226028,DB00907,Cocaine
,10503947,elimination half-lives,"The elimination half-lives of cocaine and norcocaine were similar (28-33 min), that for ecgonine methylester (60-71 min) was approximately twice this and for benzoylecgonine was 40-44 min.","Cocaine, norcocaine, ecgonine methylester and benzoylecgonine pharmacokinetics in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10503947/),min,40-44,226029,DB00907,Cocaine
,10503947,clearance,Cocaine clearance (155-158 ml/kg/min) was found to be in the range found in other rat studies.,"Cocaine, norcocaine, ecgonine methylester and benzoylecgonine pharmacokinetics in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10503947/),[ml] / [kg·min],155-158,226030,DB00907,Cocaine
,2046336,distribution volume,"Under assumptions of the model, calculated parameters indicated a BZ distribution volume of 50 L, a half-time for BZ formation of 1.9 h and a BZ excretion half-time of 4.7 h.",A kinetic model of benzoylecgonine disposition after cocaine administration in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046336/),l,50,228504,DB00907,Cocaine
,2046336,half-time for BZ formation,"Under assumptions of the model, calculated parameters indicated a BZ distribution volume of 50 L, a half-time for BZ formation of 1.9 h and a BZ excretion half-time of 4.7 h.",A kinetic model of benzoylecgonine disposition after cocaine administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046336/),h,1.9,228505,DB00907,Cocaine
,2046336,excretion half-time,"Under assumptions of the model, calculated parameters indicated a BZ distribution volume of 50 L, a half-time for BZ formation of 1.9 h and a BZ excretion half-time of 4.7 h.",A kinetic model of benzoylecgonine disposition after cocaine administration in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2046336/),h,4.7,228506,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),[ml] / [min],0.125,229003,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),[ml] / [min],0.1875,229004,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),[ml] / [min],0.375,229005,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),[ml] / [min],0.75,229006,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),[ml] / [min],3,229007,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),,240,229008,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),,160,229009,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),,80,229010,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),,40,229011,DB00907,Cocaine
,9683003,rate of delivery,"With unit dose (0.056 mg/kg per infusion for one monkey and 0.032 mg/kg per infusion for the rest) and infusion volume (0.5 ml) held constant, the rate of delivery was manipulated (0.125, 0.1875, 0.375, 0.75 and 3 ml/min, with infusions lasting 240, 160, 80, 40, and 10 s, respectively).",Effects of delivery rate and non-contingent infusion of cocaine on cocaine self-administration in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9683003/),,10,229012,DB00907,Cocaine
,2019993,bioavailable doses,"The bioavailable doses of cocaine were 0.26 +/- 0.05 and 1.54 +/- 0.46 mg/kg, after 1.5- and 5.0-min exposures, respectively.",Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019993/),[mg] / [kg],0.26,229835,DB00907,Cocaine
,2019993,bioavailable doses,"The bioavailable doses of cocaine were 0.26 +/- 0.05 and 1.54 +/- 0.46 mg/kg, after 1.5- and 5.0-min exposures, respectively.",Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019993/),[mg] / [kg],1.54,229836,DB00907,Cocaine
,2019993,Peak cocaine plasma concentrations,"Peak cocaine plasma concentrations of 95 +/- 26 and 205 +/- 58 ng/ml, for the 1.5- and 5.0-min exposures, respectively, occurred 1 min after the start of exposure.",Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019993/),[ng] / [ml],95,229837,DB00907,Cocaine
,2019993,Peak cocaine plasma concentrations,"Peak cocaine plasma concentrations of 95 +/- 26 and 205 +/- 58 ng/ml, for the 1.5- and 5.0-min exposures, respectively, occurred 1 min after the start of exposure.",Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019993/),[ng] / [ml],205,229838,DB00907,Cocaine
,2019993,bioavailability,Increasing the duration of exposure significantly increased the bioavailability from 0.29 to 1.03 (P less than .05).,Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019993/),,0.29,229839,DB00907,Cocaine
,2019993,bioavailability,Increasing the duration of exposure significantly increased the bioavailability from 0.29 to 1.03 (P less than .05).,Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019993/),,1.03,229840,DB00907,Cocaine
,7988363,plasma half-life,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),min,10,233054,DB00907,Cocaine
,7988363,plasma half-life,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),min,18.7,233055,DB00907,Cocaine
,7988363,apparent volume of distribution,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),,73,233056,DB00907,Cocaine
,7988363,apparent volume of distribution,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),,51,233057,DB00907,Cocaine
,7988363,clearance,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),,5.37,233058,DB00907,Cocaine
less,2614690,half-lives,The pharmacokinetic profiles of 1a and 2 indicate half-lives of less than 20 min in the brain and plasma.,Mass spectrometric studies of cocaine disposition in animals and humans using stable isotope-labeled analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614690/),min,20,234833,DB00907,Cocaine
,17519385,plasma elimination half-life,"3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively.",Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519385/),h,1.9,235022,DB00907,Cocaine
,17519385,plasma elimination half-life,"3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively.",Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519385/),h,0.5,235023,DB00907,Cocaine
,17519385,plasma elimination half-life,"3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively.",Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519385/),h,21.1,235024,DB00907,Cocaine
,8577180,half life,Plasma concentrations of COC decreased rapidly with a half life of 15.7 min.,"Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),min,15.7,240159,DB00907,Cocaine
,8577180,COC,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],296,240160,DB00907,Cocaine
,8577180,COC,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],225,240161,DB00907,Cocaine
,8577180,COC,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],187,240162,DB00907,Cocaine
,8577180,COC,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],80,240163,DB00907,Cocaine
,8577180,concentrations,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],296,240164,DB00907,Cocaine
,8577180,concentrations,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],225,240165,DB00907,Cocaine
,8577180,concentrations,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],187,240166,DB00907,Cocaine
,8577180,concentrations,"Mean COC concentrations in the drug-treated group (n = 7) for the four timepoints were 296, 225, 187, and 80 ng/mL, respectively.","Cocaine, ecgonine methyl ester, and benzoylecgonine plasma profiles in rhesus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8577180/),[ng] / [ml],80,240167,DB00907,Cocaine
,17003230,permeability,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),[cm] / [s],8.26 to 32.23,241624,DB00907,Cocaine
,17003230,permeability,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),[cm] / [s],1.37 to 21.65,241625,DB00907,Cocaine
,17003230,efflux ratios,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,2.1 to 6.9,241626,DB00907,Cocaine
,17003230,efflux ratios,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,3,241627,DB00907,Cocaine
,17003230,brain-to-plasma partition coefficient,"The brain uptake for 4'-Cl and 4',4''-diCl BZT was comparable and higher than previously reported for cocaine (brain-to-plasma partition coefficient = 4.6-4.7 versus 2.1 for cocaine).","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,4.6-4.7,241628,DB00907,Cocaine
,17003230,brain-to-plasma partition coefficient,"The brain uptake for 4'-Cl and 4',4''-diCl BZT was comparable and higher than previously reported for cocaine (brain-to-plasma partition coefficient = 4.6-4.7 versus 2.1 for cocaine).","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,2.1,241629,DB00907,Cocaine
,7924765,AUC,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[mg] / [l·min],148.9,242979,DB00907,Cocaine
,7924765,systemic clearance,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[l] / [kg·min],0.041,242980,DB00907,Cocaine
,7924765,volume of distribution,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[l] / [kg],1.543,242981,DB00907,Cocaine
,7924765,t1/2 beta,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,29.4,242982,DB00907,Cocaine
,7924765,distribution,"Cocaine followed two-compartment model kinetics with distribution and elimination half-lives of 0.3 +/- 0.1 and 58.0 +/- 18.0 min, respectively.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,0.3,242983,DB00907,Cocaine
,7924765,elimination half-lives,"Cocaine followed two-compartment model kinetics with distribution and elimination half-lives of 0.3 +/- 0.1 and 58.0 +/- 18.0 min, respectively.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,58.0,242984,DB00907,Cocaine
,7924765,systemic clearance,Labetalol significantly decreased systemic clearance to 0.029 +/- 0.004 liters/min/kg.,Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[l] / [kg·min],0.029,242985,DB00907,Cocaine
,7924765,elimination half-life,BE kinetics revealed a elimination half-life of 230.0 +/- 83.2 min.,Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,230.0,242986,DB00907,Cocaine
,25445957,distribution,"In control mice, a two-compartment pharmacokinetic model generated values for cocaethylene distribution and terminal elimination half-lives of 0.5 and 8.1 min respectively.",The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25445957/),min,0.5,246138,DB00907,Cocaine
,25445957,terminal elimination half-lives,"In control mice, a two-compartment pharmacokinetic model generated values for cocaethylene distribution and terminal elimination half-lives of 0.5 and 8.1 min respectively.",The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25445957/),min,8.1,246139,DB00907,Cocaine
,25445957,distribution half-life,"A three-compartment model resolved an initial distribution half-life of 4.4 min and a second distribution half-life of 4.2 h, and a terminal elimination half-life of 7.8 days.",The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25445957/),min,4.4,246140,DB00907,Cocaine
,25445957,distribution half-life,"A three-compartment model resolved an initial distribution half-life of 4.4 min and a second distribution half-life of 4.2 h, and a terminal elimination half-life of 7.8 days.",The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25445957/),h,4.2,246141,DB00907,Cocaine
,25445957,terminal elimination half-life,"A three-compartment model resolved an initial distribution half-life of 4.4 min and a second distribution half-life of 4.2 h, and a terminal elimination half-life of 7.8 days.",The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25445957/),d,7.8,246142,DB00907,Cocaine
,2626213,milk/blood ratio,"Cocaine is sufficiently stable in milk to assume that any cocaine entering breast milk from the blood stream will be available to the suckling infant, and after administering radioactive cocaine to lactating dams, the milk/blood ratio for cocaine averaged 7.8.","Pharmacokinetics of cocaine: basic studies of route, dosage, pregnancy and lactation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2626213/),,7.8,246897,DB00907,Cocaine
,9013291,pKb,"These findings may be due, at least in part, to the greater hydrophobicity of CE relative to COC and to the lower pKb of CE (8.23) than that of COC (8.60).",Cocaine- and cocaethylene-creatinine clearance ratios in humans. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013291/),,8.23,248689,DB00907,Cocaine
,9013291,pKb,"These findings may be due, at least in part, to the greater hydrophobicity of CE relative to COC and to the lower pKb of CE (8.23) than that of COC (8.60).",Cocaine- and cocaethylene-creatinine clearance ratios in humans. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013291/),,8.60,248690,DB00907,Cocaine
,21494909,half-life,"Oral administration of SN79 reached peak in vivo concentrations after 1.5 h and exhibited a half-life of just over 7.5 h in male, Sprague-Dawley rats.","Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21494909/),h,7.5,250164,DB00907,Cocaine
,18514640,t(1/2),"As assessed from the time course of cocaine hydrolyzing activity in plasma, Albu-CocH redistributed into extracellular fluid (16% of estimated total body water) with a t(1/2) of 0.66h and it underwent elimination with a t(1/2) of 8h.",An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514640/),h,0.66,250395,DB00907,Cocaine
,18514640,t(1/2),"As assessed from the time course of cocaine hydrolyzing activity in plasma, Albu-CocH redistributed into extracellular fluid (16% of estimated total body water) with a t(1/2) of 0.66h and it underwent elimination with a t(1/2) of 8h.",An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514640/),h,8,250396,DB00907,Cocaine
,11043647,terminal T(1/2),Results indicated a cocaine terminal T(1/2) of 3.8 h in plasma and 7.9 h in saliva.,Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043647/),h,3.8,251569,DB00907,Cocaine
,11043647,terminal T(1/2),Results indicated a cocaine terminal T(1/2) of 3.8 h in plasma and 7.9 h in saliva.,Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043647/),h,7.9,251570,DB00907,Cocaine
,11043647,terminal T(1/2),The terminal T(1/2) of benzoylecgonine was 6.6 h in plasma and 9.2 h in saliva.,Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043647/),h,6.6,251571,DB00907,Cocaine
,11043647,terminal T(1/2),The terminal T(1/2) of benzoylecgonine was 6.6 h in plasma and 9.2 h in saliva.,Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043647/),h,9.2,251572,DB00907,Cocaine
,15689153,Ki,"Benzazepines 1 and 2 (SCH 23390 and SCH 39166, respectively) are two classical benzazepine D1/D5 antagonists, with Ki values 1.4 and 1.2 nM, respectively.","Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689153/),nM,1.4,253722,DB00907,Cocaine
,15689153,Ki,"Benzazepines 1 and 2 (SCH 23390 and SCH 39166, respectively) are two classical benzazepine D1/D5 antagonists, with Ki values 1.4 and 1.2 nM, respectively.","Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689153/),nM,1.2,253723,DB00907,Cocaine
,8971868,global T1/2,"The mean (+/- S.D.) global T1/2 values of the crack-only (75 +/- 39 min) and crack plus tobacco users (22 +/- 10 min) were significantly shorter (P < 0.02 and P < 0.001, respectively) than from the lungs of the non-smoking controls (124 +/- 29 min).",Does detoxification reverse the acute lung injury of crack smokers? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971868/),min,75,254764,DB00907,Cocaine
,8971868,global T1/2,"The mean (+/- S.D.) global T1/2 values of the crack-only (75 +/- 39 min) and crack plus tobacco users (22 +/- 10 min) were significantly shorter (P < 0.02 and P < 0.001, respectively) than from the lungs of the non-smoking controls (124 +/- 29 min).",Does detoxification reverse the acute lung injury of crack smokers? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971868/),min,22,254765,DB00907,Cocaine
,8971868,global T1/2,"The mean (+/- S.D.) global T1/2 values of the crack-only (75 +/- 39 min) and crack plus tobacco users (22 +/- 10 min) were significantly shorter (P < 0.02 and P < 0.001, respectively) than from the lungs of the non-smoking controls (124 +/- 29 min).",Does detoxification reverse the acute lung injury of crack smokers? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971868/),min,124,254766,DB00907,Cocaine
,22844238,area under the cocaine concentration versus time curve (AUC),"The threshold concentration of cocaine in brain required to produce physiological effects has been estimated to be 0.22±0.07 µM, and the threshold area under the cocaine concentration versus time curve (AUC) value in brain (denoted by AUC2(∞)) required to produce physiological effects has been estimated to be 7.9±2.7 µM·min.",Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22844238/),min·μM,7.9,256198,DB00907,Cocaine
,22844238,AUC2(∞),"The threshold concentration of cocaine in brain required to produce physiological effects has been estimated to be 0.22±0.07 µM, and the threshold area under the cocaine concentration versus time curve (AUC) value in brain (denoted by AUC2(∞)) required to produce physiological effects has been estimated to be 7.9±2.7 µM·min.",Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22844238/),min·μM,7.9,256199,DB00907,Cocaine
,1865351,Clearance (Cl),Clearance (Cl) was not dose-dependent and the average +/- S.D. was 59 +/- 16 ml/min/kg over the i.v. dose range of 2 to 12 mg/kg.,Cocaine pharmacokinetics in the pregnant guinea pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),[ml] / [kg·min],59,260714,DB00907,Cocaine
,1865351,Vdss,Vdss was 2.1 and 3.9 l/kg.,Cocaine pharmacokinetics in the pregnant guinea pig. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),[l] / [kg],2.1,260715,DB00907,Cocaine
,1865351,Vdss,Vdss was 2.1 and 3.9 l/kg.,Cocaine pharmacokinetics in the pregnant guinea pig. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),[l] / [kg],3.9,260716,DB00907,Cocaine
,1865351,MRT time,"MRT time was 42 and 57 min, and elimination T1/2 was 34 and 49 min at the 2 and 4 mg/kg dose, respectively.",Cocaine pharmacokinetics in the pregnant guinea pig. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),min,42,260717,DB00907,Cocaine
,1865351,MRT time,"MRT time was 42 and 57 min, and elimination T1/2 was 34 and 49 min at the 2 and 4 mg/kg dose, respectively.",Cocaine pharmacokinetics in the pregnant guinea pig. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),min,57,260718,DB00907,Cocaine
,1865351,elimination T1/2,"MRT time was 42 and 57 min, and elimination T1/2 was 34 and 49 min at the 2 and 4 mg/kg dose, respectively.",Cocaine pharmacokinetics in the pregnant guinea pig. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),min,34,260719,DB00907,Cocaine
,1865351,elimination T1/2,"MRT time was 42 and 57 min, and elimination T1/2 was 34 and 49 min at the 2 and 4 mg/kg dose, respectively.",Cocaine pharmacokinetics in the pregnant guinea pig. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),min,49,260720,DB00907,Cocaine
,1865351,T1/2,Absorption of COC s.c. was nearly complete (84%) and had a T1/2 of 51 min.,Cocaine pharmacokinetics in the pregnant guinea pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1865351/),min,51,260721,DB00907,Cocaine
,12130735,k(cat),"Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved k(cat) (154 min(-1) versus 4.1 min(-1)) and only slightly increased K(M) (18 microM versus 4.5 microM).",Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130735/),1/[min],154,264950,DB00907,Cocaine
,12130735,k(cat),"Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved k(cat) (154 min(-1) versus 4.1 min(-1)) and only slightly increased K(M) (18 microM versus 4.5 microM).",Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130735/),1/[min],4.1,264951,DB00907,Cocaine
,12130735,K(M),"Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved k(cat) (154 min(-1) versus 4.1 min(-1)) and only slightly increased K(M) (18 microM versus 4.5 microM).",Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130735/),μM,18,264952,DB00907,Cocaine
,12130735,K(M),"Compared with wild-type BChE, this enzyme hydrolyzes cocaine with 40-fold improved k(cat) (154 min(-1) versus 4.1 min(-1)) and only slightly increased K(M) (18 microM versus 4.5 microM).",Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130735/),μM,4.5,264953,DB00907,Cocaine
,12130735,half-life,"In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min.",Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130735/),min,52,264954,DB00907,Cocaine
,12130735,half-life,"In rats given this hydrolase (3 mg/kg i.v.) 10 min before cocaine challenge (6.8 mg/kg i.v.), cocaine half-life was reduced from 52 min to 18 min.",Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130735/),min,18,264955,DB00907,Cocaine
,16413604,elimination half-life,"The elimination half-life of methamphetamine was approximately 12 h, and selegiline did not alter clearance of methamphetamine.",A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413604/),h,12,265657,DB00907,Cocaine
,18425847,R(i),"In vivo, GA2-50 showed high brain uptake (R(i) approximately 10), large volume of distribution (V(ss) = 37 L/kg), and long elimination half-life (t((1/2)) = 19 h).",The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18425847/),,10,267420,DB00907,Cocaine
,18425847,volume of distribution (V(ss),"In vivo, GA2-50 showed high brain uptake (R(i) approximately 10), large volume of distribution (V(ss) = 37 L/kg), and long elimination half-life (t((1/2)) = 19 h).",The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18425847/),[l] / [kg],37,267421,DB00907,Cocaine
,18425847,elimination half-life (t((1/2)),"In vivo, GA2-50 showed high brain uptake (R(i) approximately 10), large volume of distribution (V(ss) = 37 L/kg), and long elimination half-life (t((1/2)) = 19 h).",The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18425847/),h,19,267422,DB00907,Cocaine
,7771915,uptake,"The uptake of [11C]methylphenidate in the brain was high (mean +/- SD, 7.5% +/- 1.5%), and the maximal concentration occurred in striatum.",Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7771915/),%,7.5,268333,DB00907,Cocaine
,7771915,Clearance,Clearance of [11C]methylphenidate from striatum (90 minutes) was significantly slower than that of [11C]cocaine (20 minutes).,Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7771915/),min,90,268334,DB00907,Cocaine
,7771915,Clearance,Clearance of [11C]methylphenidate from striatum (90 minutes) was significantly slower than that of [11C]cocaine (20 minutes).,Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7771915/),min,20,268335,DB00907,Cocaine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],71.7,268712,DB00907,Cocaine
,27940077,t1/2,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),min,116,268713,DB00907,Cocaine
,27940077,clearance,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ml] / [kg·min],6.25,268714,DB00907,Cocaine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],191,268715,DB00907,Cocaine
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],63,268716,DB00907,Cocaine
,27940077,ED50,The ED50 value of nicotine to produce discriminative stimulus effects was 0.013 mg/kg.,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.013,268717,DB00907,Cocaine
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.00015,268718,DB00907,Cocaine
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.031,268719,DB00907,Cocaine
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.58,268720,DB00907,Cocaine
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.45,268721,DB00907,Cocaine
,9575250,volume of distribution,The volume of distribution in the striatum was 94+/-24 ml/ml.,"Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9575250/),[ml] / [ml],94,269496,DB00907,Cocaine
,9575250,effective dose,Radiation exposure to the study subject is 0.022+/-0.004 mSv/MBq (effective dose).,"Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9575250/),[msv] / [Mbq],0.022,269497,DB00907,Cocaine
,9506757,Peak cocaine plasma levels,Peak cocaine plasma levels averaged 101.2 +/- 14.6 ng/mL.,Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),[ng] / [ml],101.2,273514,DB00907,Cocaine
,9506757,t(max) (observed time to maximum concentration),Pharmacokinetic analysis showed that the t(max) (observed time to maximum concentration) values for cocaine (6.0 +/- 1.4 min) and ACTH (7.3 +/- 1.2 min) were almost identical.,Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,6.0,273515,DB00907,Cocaine
,9506757,t(max) (observed time to maximum concentration),Pharmacokinetic analysis showed that the t(max) (observed time to maximum concentration) values for cocaine (6.0 +/- 1.4 min) and ACTH (7.3 +/- 1.2 min) were almost identical.,Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,7.3,273516,DB00907,Cocaine
,9506757,area under the curve,"The area under the curve for plasma cocaine was 6463 +/- 1070 ng/min x mL, and the area under the curve for ACTH was 1873 +/- 188 pmol/min x L.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),[ng] / [min·ml],6463,273517,DB00907,Cocaine
,9506757,area under the curve,"The area under the curve for plasma cocaine was 6463 +/- 1070 ng/min x mL, and the area under the curve for ACTH was 1873 +/- 188 pmol/min x L.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),[pM] / [l·min],1873,273518,DB00907,Cocaine
,9506757,half-life,"The mean half-life for plasma cocaine was 46.7 +/- 4.0 min, and that for ACTH was 35.8 +/- 5.1 min.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,46.7,273519,DB00907,Cocaine
,9506757,half-life,"The mean half-life for plasma cocaine was 46.7 +/- 4.0 min, and that for ACTH was 35.8 +/- 5.1 min.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,35.8,273520,DB00907,Cocaine
